Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group
It is more than 20 years since the neuraminidase inhibitors, oseltamivir and zanamivir were approved for the treatment and prevention of influenza. Guidelines for global surveillance and methods for evaluating resistance were established initially by the Neuraminidase Inhibitor Susceptibility Networ...
Saved in:
| Published in | Antiviral research Vol. 194; p. 105158 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier B.V
01.10.2021
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | It is more than 20 years since the neuraminidase inhibitors, oseltamivir and zanamivir were approved for the treatment and prevention of influenza. Guidelines for global surveillance and methods for evaluating resistance were established initially by the Neuraminidase Inhibitor Susceptibility Network (NISN), which merged 10 years ago with the International Society for influenza and other Respiratory Virus Diseases (isirv) to become the isirv-Antiviral Group (isirv-AVG). With the ongoing development of new influenza polymerase inhibitors and recent approval of baloxavir marboxil, the isirv-AVG held a closed meeting in August 2019 to discuss the impact of resistance to these inhibitors. Following this meeting and review of the current literature, this article is intended to summarize current knowledge regarding the clinical impact of resistance to polymerase inhibitors and approaches for surveillance and methods for laboratory evaluation of resistance, both in vitro and in animal models. We highlight limitations and gaps in current knowledge and suggest some strategies for addressing these gaps, including the need for additional clinical studies of influenza antiviral drug combinations. Lessons learned from influenza resistance monitoring may also be helpful for establishing future drug susceptibility surveillance and testing for SARS-CoV-2.
•Current knowledge regarding the clinical impact of resistance to influenza polymerase inhibitors is summarized.•Current surveillance strategies for detection of variants with reduced susceptibility to polymerase inhibitors are discussed.•Methods for laboratory evaluation of resistance in vitro and in animal models, along with their limitations are presented. |
|---|---|
| AbstractList | It is more than 20 years since the neuraminidase inhibitors, oseltamivir and zanamivir were approved for the treatment and prevention of influenza. Guidelines for global surveillance and methods for evaluating resistance were established initially by the Neuraminidase Inhibitor Susceptibility Network (NISN), which merged 10 years ago with the International Society for influenza and other Respiratory Virus Diseases (isirv) to become the isirv-Antiviral Group (isirv-AVG). With the ongoing development of new influenza polymerase inhibitors and recent approval of baloxavir marboxil, the isirv-AVG held a closed meeting in August 2019 to discuss the impact of resistance to these inhibitors. Following this meeting and review of the current literature, this article is intended to summarize current knowledge regarding the clinical impact of resistance to polymerase inhibitors and approaches for surveillance and methods for laboratory evaluation of resistance, both in vitro and in animal models. We highlight limitations and gaps in current knowledge and suggest some strategies for addressing these gaps, including the need for additional clinical studies of influenza antiviral drug combinations. Lessons learned from influenza resistance monitoring may also be helpful for establishing future drug susceptibility surveillance and testing for SARS-CoV-2.It is more than 20 years since the neuraminidase inhibitors, oseltamivir and zanamivir were approved for the treatment and prevention of influenza. Guidelines for global surveillance and methods for evaluating resistance were established initially by the Neuraminidase Inhibitor Susceptibility Network (NISN), which merged 10 years ago with the International Society for influenza and other Respiratory Virus Diseases (isirv) to become the isirv-Antiviral Group (isirv-AVG). With the ongoing development of new influenza polymerase inhibitors and recent approval of baloxavir marboxil, the isirv-AVG held a closed meeting in August 2019 to discuss the impact of resistance to these inhibitors. Following this meeting and review of the current literature, this article is intended to summarize current knowledge regarding the clinical impact of resistance to polymerase inhibitors and approaches for surveillance and methods for laboratory evaluation of resistance, both in vitro and in animal models. We highlight limitations and gaps in current knowledge and suggest some strategies for addressing these gaps, including the need for additional clinical studies of influenza antiviral drug combinations. Lessons learned from influenza resistance monitoring may also be helpful for establishing future drug susceptibility surveillance and testing for SARS-CoV-2. It is more than 20 years since the neuraminidase inhibitors, oseltamivir and zanamivir were approved for the treatment and prevention of influenza. Guidelines for global surveillance and methods for evaluating resistance were established initially by the Neuraminidase Inhibitor Susceptibility Network (NISN), which merged 10 years ago with the International Society for influenza and other Respiratory Virus Diseases (isirv) to become the isirv-Antiviral Group (isirv-AVG). With the ongoing development of new influenza polymerase inhibitors and recent approval of baloxavir marboxil, the isirv-AVG held a closed meeting in August 2019 to discuss the impact of resistance to these inhibitors. Following this meeting and review of the current literature, this article is intended to summarize current knowledge regarding the clinical impact of resistance to polymerase inhibitors and approaches for surveillance and methods for laboratory evaluation of resistance, both in vitro and in animal models. We highlight limitations and gaps in current knowledge and suggest some strategies for addressing these gaps, including the need for additional clinical studies of influenza antiviral drug combinations. Lessons learned from influenza resistance monitoring may also be helpful for establishing future drug susceptibility surveillance and testing for SARS-CoV-2. •Current knowledge regarding the clinical impact of resistance to influenza polymerase inhibitors is summarized.•Current surveillance strategies for detection of variants with reduced susceptibility to polymerase inhibitors are discussed.•Methods for laboratory evaluation of resistance in vitro and in animal models, along with their limitations are presented. It is more than 20 years since the neuraminidase inhibitors, oseltamivir and zanamivir were approved for the treatment and prevention of influenza. Guidelines for global surveillance and methods for evaluating resistance were established initially by the Neuraminidase Inhibitor Susceptibility Network (NISN), which merged 10 years ago with the International Society for influenza and other Respiratory Virus Diseases (isirv) to become the isirv-Antiviral Group (isirv-AVG). With the ongoing development of new influenza polymerase inhibitors and recent approval of baloxavir marboxil, the isirv-AVG held a closed meeting in August 2019 to discuss the impact of resistance to these inhibitors. Following this meeting and review of the current literature, this article is intended to summarize current knowledge regarding the clinical impact of resistance to polymerase inhibitors and approaches for surveillance and methods for laboratory evaluation of resistance, both in vitro and in animal models. We highlight limitations and gaps in current knowledge and suggest some strategies for addressing these gaps, including the need for additional clinical studies of influenza antiviral drug combinations. Lessons learned from influenza resistance monitoring may also be helpful for establishing future drug susceptibility surveillance and testing for SARS-CoV-2. It is more than 20 years since the neuraminidase inhibitors, oseltamivir and zanamivir were approved for the treatment and prevention of influenza. Guidelines for global surveillance and methods for evaluating resistance were established initially by the Neuraminidase Inhibitor Susceptibility Network (NISN), which merged 10 years ago with the International Society for influenza and other Respiratory Virus Diseases (isirv) to become the isirv-Antiviral Group (isirv-AVG). With the ongoing development of new influenza polymerase inhibitors and recent approval of baloxavir marboxil, the isirv-AVG held a closed meeting in August 2019 to discuss the impact of resistance to these inhibitors. Following this meeting and review of the current literature, this article is intended to summarize current knowledge regarding the clinical impact of resistance to polymerase inhibitors and approaches for surveillance and methods for laboratory evaluation of resistance, both in vitro and in animal models. We highlight limitations and gaps in current knowledge and suggest some strategies for addressing these gaps, including the need for additional clinical studies of influenza antiviral drug combinations. Lessons learned from influenza resistance monitoring may also be helpful for establishing future drug susceptibility surveillance and testing for SARS-CoV-2. |
| ArticleNumber | 105158 |
| Author | McKimm-Breschkin, Jennifer L. Takashita, Emi Govorkova, Elena A. Ison, Michael G. Gubareva, Larisa V. Hayden, Frederick G. Hay, Alan J. |
| AuthorAffiliation | c The Francis Crick Institute, London, UK e Department of Infectious Diseases, St Jude Children’s Research Hospital, Memphis, TN, USA g Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Victoria, Australia d Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA f National Institute of Infectious Diseases, Tokyo, Japan a Divisions of Infectious Diseases and Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA b Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, VA, USA |
| AuthorAffiliation_xml | – name: g Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Victoria, Australia – name: f National Institute of Infectious Diseases, Tokyo, Japan – name: a Divisions of Infectious Diseases and Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA – name: c The Francis Crick Institute, London, UK – name: d Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA – name: b Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, VA, USA – name: e Department of Infectious Diseases, St Jude Children’s Research Hospital, Memphis, TN, USA |
| Author_xml | – sequence: 1 givenname: Michael G. orcidid: 0000-0003-3347-9671 surname: Ison fullname: Ison, Michael G. email: mgison@northwestern.edu organization: Divisions of Infectious Diseases and Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA – sequence: 2 givenname: Frederick G. orcidid: 0000-0001-8707-0375 surname: Hayden fullname: Hayden, Frederick G. email: fgh@virginia.edu organization: Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, VA, USA – sequence: 3 givenname: Alan J. surname: Hay fullname: Hay, Alan J. email: Alan.Hay@crick.ac.uk organization: The Francis Crick Institute, London, UK – sequence: 4 givenname: Larisa V. surname: Gubareva fullname: Gubareva, Larisa V. email: LGubareva@cdc.gov organization: Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA – sequence: 5 givenname: Elena A. surname: Govorkova fullname: Govorkova, Elena A. email: Elena.Govorkova@stjude.org organization: Department of Infectious Diseases, St Jude Children's Research Hospital, Memphis, TN, USA – sequence: 6 givenname: Emi surname: Takashita fullname: Takashita, Emi email: emitaka@nih.go.jp organization: National Institute of Infectious Diseases, Tokyo, Japan – sequence: 7 givenname: Jennifer L. orcidid: 0000-0002-2345-6786 surname: McKimm-Breschkin fullname: McKimm-Breschkin, Jennifer L. email: jmbvirology@gmail.com organization: Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Victoria, Australia |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34363859$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUcuKFDEUDTLi9Iz-gmbppto8KlUVQaEZfAwMuNF1SCW3ptNUJWWSahjBfzdNTzfqZlYh957H5ZwrdOGDB4TeULKmhDbvdmvts9u7qMc1I4yWqaCie4ZWtGtZJYlsLtCqIJuKi5pdoquUdoSQppXdC3TJa97wTsgV-n3rh3EB_0vjOYwPE0SdADu_db3LIeIIyaWsvYH3eJMSpDSBzzgMOG8BmyXGw7cgMpyGOmZc4U2hziGeoS65uMeb09X4PoZlfomeD3pM8OrxvUY_Pn_6fvO1uvv25fZmc1cZUdNcUc2ZYEx0tDFUWGFb3hnec6mtFIJZY6ztG02l0X0jBJQw2CDbrueaUtsRfo0-HnXnpZ_AmnJzuUHN0U06Pqignfp3491W3Ye9koQW37YIvH0UiOHnAimrySUD46g9hCUpJoSseU2kLNDXf3udTU6ZF8CHI8DEkFKEQRlX8nPhYO1GRYk6dKx26tyxOnSsjh0Xfvsf_2TxNHNzZELJeu8gqmQclG6ti2CyssE9qfEH0ujJMQ |
| CitedBy_id | crossref_primary_10_1038_s41467_023_37773_6 crossref_primary_10_1016_j_ejmech_2022_115035 crossref_primary_10_1080_08927022_2023_2210690 crossref_primary_10_1093_glycob_cwac054 crossref_primary_10_1093_ofid_ofaf058 crossref_primary_10_1097_MCP_0000000000000858 crossref_primary_10_3390_ijms24010678 crossref_primary_10_1038_s42003_024_06173_x crossref_primary_10_1021_acs_jmedchem_1c01612 crossref_primary_10_1002_adtp_202400169 crossref_primary_10_1016_j_antiviral_2022_105499 crossref_primary_10_1016_j_antiviral_2022_105296 crossref_primary_10_1039_D4AY00508B crossref_primary_10_3390_ijms232012244 crossref_primary_10_1111_tid_13866 crossref_primary_10_1021_acs_jmedchem_1c02013 crossref_primary_10_1371_journal_ppat_1010698 crossref_primary_10_3390_ph17050661 crossref_primary_10_1089_adt_2024_075 crossref_primary_10_1128_mbio_02815_22 crossref_primary_10_1016_j_antiviral_2022_105369 crossref_primary_10_1016_j_antiviral_2023_105701 crossref_primary_10_3390_jof8010001 crossref_primary_10_1016_j_antiviral_2022_105281 crossref_primary_10_1016_j_jiac_2022_02_001 |
| Cites_doi | 10.2807/ese.13.05.08026-en 10.1177/095632020301400502 10.1016/j.ebiom.2020.103125 10.1002/med.21401 10.1073/pnas.1916825117 10.3389/fmicb.2018.03026 10.1128/JVI.00373-10 10.1371/journal.ppat.1009527 10.3201/eid2510.190607 10.1093/infdis/jiaa061 10.1093/infdis/jiz665 10.1038/s41467-020-16585-y 10.1093/infdis/jiab196 10.1371/journal.pone.0023627 10.1136/bmj.f2865 10.1038/nature14009 10.1128/JCM.03265-13 10.1093/jac/dkaa393 10.1073/pnas.1811345115 10.1038/363418a0 10.1111/irv.12565 10.1128/AAC.47.7.2264-2272.2003 10.1097/INF.0b013e3181de9d24 10.1093/infdis/jis571 10.1038/s41598-019-39276-1 10.1097/INF.0000000000002748 10.1111/irv.12661 10.1016/j.antiviral.2020.104828 10.1016/S0140-6736(05)67338-2 10.1111/irv.12728 10.7883/yoken.JJID.2019.210 10.1111/irv.12821 10.1093/jac/dky462 10.3851/IMP1194 10.1093/infdis/jiq005 10.1128/mSphere.00822-19 10.3390/v13071196 10.3390/v11111066 10.2807/1560-7917.ES.2019.24.12.1900170 10.1016/j.antiviral.2019.02.007 10.1038/s41598-018-27890-4 10.1128/AAC.46.4.977-981.2002 10.1093/infdis/164.5.969 10.1016/j.antiviral.2020.104718 10.1086/648424 10.2807/1560-7917.ES.2019.24.3.1800666 10.1001/archinte.160.21.3234 10.1016/S2213-2600(14)70041-4 10.3201/eid2511.190757 10.1111/irv.12047 10.1021/jm5007275 10.1016/S0140-6736(14)62449-1 10.1056/NEJMoa1716197 10.1128/AAC.04623-14 10.1111/irv.12760 10.1038/nature14008 10.1093/infdis/jiz656 10.1111/irv.12534 10.1128/JCM.41.2.742-750.2003 10.1038/s41564-019-0609-0 10.1128/AAC.04836-14 10.1093/infdis/jis509 10.1128/JVI.73.4.3473-3476.1999 10.1016/j.antiviral.2018.10.008 10.1093/cid/ciz904 10.1128/JVI.00689-10 10.1016/j.antiviral.2016.06.007 10.1016/j.antiviral.2021.105036 10.1016/j.antiviral.2017.11.013 10.1016/j.antiviral.2019.104545 10.1128/JVI.01109-09 10.1111/irv.12725 10.1126/science.1187816 10.1016/j.antiviral.2020.104906 10.1136/bmj.c7258 10.1073/pnas.76.4.1618 10.1186/s12879-020-05205-1 10.1371/journal.ppat.1003343 10.1098/rsif.2011.0427 10.1093/infdis/jiz418 10.1097/INF.0000000000002747 10.1016/S1473-3099(20)30004-9 10.1128/AAC.01417-09 10.1016/j.antiviral.2018.07.001 10.1101/cshperspect.a038398 10.1093/cid/cis1220 10.1128/JVI.77.15.8418-8425.2003 10.1371/journal.pone.0200849 10.3851/IMP2874 10.1056/NEJMoa1915341 10.3851/IMP3189 10.1128/AAC.01339-05 10.1016/j.jamda.2005.08.006 10.1097/QCO.0000000000000532 10.1093/cid/ciz908 10.1021/ja963036t 10.1038/nature07745 10.1099/jgv.0.001029 10.3851/IMP3212 10.1016/j.antiviral.2020.104807 10.1016/j.antiviral.2009.03.003 10.2807/1560-7917.ES.2019.24.3.1800698 10.1002/jmv.22101 10.1016/j.antiviral.2016.10.009 10.1371/journal.pone.0217307 10.1128/JVI.02346-12 10.1016/j.tibtech.2019.09.009 10.1016/j.antiviral.2021.105035 10.1038/s41564-019-0433-6 10.1542/peds.80.2.275 10.1093/infdis/jiaa164 10.1136/bmj.331.7507.10 10.1093/infdis/jiy547 10.1371/journal.ppat.1008395 10.1093/infdis/jix606 10.1016/S1473-3099(13)70267-6 10.1038/srep26742 10.1038/s41598-019-39683-4 10.1371/journal.ppat.1008937 10.1136/bmjopen-2014-005253 10.1093/infdis/jis337 10.1086/656802 10.1093/jac/dkaa527 10.1128/AAC.01739-09 10.1056/NEJM199709253371302 10.1093/cid/cix127 10.1093/infdis/jiy410 10.1016/0092-8674(79)90052-7 |
| ContentType | Journal Article |
| Copyright | 2021 Elsevier B.V. Copyright © 2021 Elsevier B.V. All rights reserved. |
| Copyright_xml | – notice: 2021 Elsevier B.V. – notice: Copyright © 2021 Elsevier B.V. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1016/j.antiviral.2021.105158 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1872-9096 |
| EndPage | 105158 |
| ExternalDocumentID | PMC9012257 34363859 10_1016_j_antiviral_2021_105158 S0166354221001480 |
| Genre | Journal Article Review Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: Intramural CDC HHS grantid: CC999999 – fundername: NIAID NIH HHS grantid: 75N93021C00016 – fundername: NIAID NIH HHS grantid: HHSN272201400006C |
| GroupedDBID | --- --K --M .GJ .~1 0R~ 1B1 1RT 1~. 1~5 23M 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ 9JM AAAJQ AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AATCM AAXUO ABBQC ABFNM ABJNI ABLVK ABMAC ABMZM ABXDB ABYKQ ABZDS ACDAQ ACGFS ACIUM ACRLP ADBBV ADEZE ADMUD AEBSH AEKER AENEX AFFNX AFKWA AFTJW AFXIZ AGEKW AGHFR AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV C45 CJTIS CNWQP CS3 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HMG HVGLF HZ~ IHE J1W KOM LCYCR LUGTX M41 MO0 N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SCC SDF SDG SDP SES SEW SIN SPCBC SSH SSI SSP SSZ T5K TEORI WUQ ZGI ZXP ~G- AATTM AAXKI AAYWO AAYXX ABWVN ACIEU ACRPL ACVFH ADCNI ADNMO AEIPS AEUPX AFJKZ AFPUW AGCQF AGQPQ AGRNS AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP CITATION CGR CUY CVF ECM EFKBS EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c541t-1a325225816c15d5d738c3b39ad9552dccddb6a19cab655e1052f978b3a11d803 |
| IEDL.DBID | .~1 |
| ISSN | 0166-3542 1872-9096 |
| IngestDate | Thu Aug 21 17:48:44 EDT 2025 Fri Jul 11 10:37:39 EDT 2025 Mon Jul 21 06:03:06 EDT 2025 Tue Jul 01 01:32:13 EDT 2025 Thu Apr 24 22:53:10 EDT 2025 Fri Feb 23 02:43:05 EST 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Antiviral Drug resistance Influenza virus Polymerase inhibitor Baloxavir Fitness |
| Language | English |
| License | Copyright © 2021 Elsevier B.V. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c541t-1a325225816c15d5d738c3b39ad9552dccddb6a19cab655e1052f978b3a11d803 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0003-3347-9671 0000-0001-8707-0375 0000-0002-2345-6786 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/9012257 |
| PMID | 34363859 |
| PQID | 2559434099 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9012257 proquest_miscellaneous_2559434099 pubmed_primary_34363859 crossref_citationtrail_10_1016_j_antiviral_2021_105158 crossref_primary_10_1016_j_antiviral_2021_105158 elsevier_sciencedirect_doi_10_1016_j_antiviral_2021_105158 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-10-01 |
| PublicationDateYYYYMMDD | 2021-10-01 |
| PublicationDate_xml | – month: 10 year: 2021 text: 2021-10-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Antiviral research |
| PublicationTitleAlternate | Antiviral Res |
| PublicationYear | 2021 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Frise, Zhou, Zwanziger, Kuhlbusch, Clinch, Wildum, Barclay (bib24) 2019 Sweet, Hayden, Jakeman, Grambas, Hay (bib112) 1991; 164 Kiso, Yamayoshi, Murakami, Kawaoka (bib66) 2020; 221 Matrosovich, Matrosovich, Carr, Roberts, Klenk (bib79) 2003; 77 Jorquera, Mishin, Chesnokov, Nguyen, Mann, Garten, Barnes, Hodges, De La Cruz, Xu, Katz, Wentworth, Gubareva (bib60) 2019; 9 Watanabe, Chang, Kim, Chu, Ohashi, Group (bib134) 2010; 51 Uehara, Hayden, Kawaguchi, Omoto, Hurt, De Jong, Hirotsu, Sugaya, Lee, Baba, Shishido, Tsuchiya, Portsmouth, Kida (bib127) 2020; 221 Kwon, Choi, Jeong, Kim, Lee, Yoon, Hwang, Webby, Govorkova, Choi, Baek, Song (bib72) 2018; 99 Smee, Barnard, Jones (bib109) 2016; 136 Fukao, Noshi, Yamamoto, Kitano, Ando, Noda, Baba, Matsumoto, Higuchi, Ikeda, Shishido, Naito (bib27) 2019; 74 Hurt, Hardie, Wilson, Deng, Osbourn, Leang, Lee, Iannello, Gehrig, Shaw, Wark, Caldwell, Givney, Xue, Maurer-Stroh, Dwyer, Wang, Smith, Levy, Booy, Dixit, Merritt, Kelso, Dalton, Durrheim, Barr (bib49) 2012; 206 McKimm-Breschkin, Trivedi, Hampson, Hay, Klimov, Tashiro, Hayden, Zambon (bib80) 2003; 47 Lee, Zhou, Frise, Goldhill, Koszalka, Mifsud, Baba, Noda, Ando, Sato, Yuki, Shishido, Uehara, Wildum, Zwanziger, Collinson, Kuhlbusch, Clinch, Hurt, Barclay (bib76) 2020; 16 Kumar, Ison, Mira, Welte, Ha, Hui, Zhong, Saito, Katugampola, Collinson, Williams, Wildum, Ackrill, Clinch, Lee (bib71) 2020 Pflug, Guilligay, Reich, Cusack (bib97) 2014; 516 Takashita, Abe, Morita, Nagata, Fujisaki, Miura, Shirakura, Kishida, Nakamura, Kuwahara, Mitamura, Ichikawa, Yamazaki, Watanabe, Hasegawa (bib116) 2020; 180 Takashita, Kawakami, Ogawa, Morita, Fujisaki, Shirakura, Miura, Nakamura, Kishida, Kuwahara, Ota, Togashi, Saito, Mitamura, Abe, Ichikawa, Yamazaki, Watanabe, Odagiri (bib121) 2019; 24 Takada, Kawakami, Fan, Chiba, Zhong, Gu, Shimizu, Takasaki, Sakai-Tagawa, Lopes, Dutta, Khan, Kriti, van Bakel, Yamada, Watanabe, Imai, Kawaoka (bib113) 2019; 4 Soh, Malone, Eguia, Bloom (bib110) 2021 Reich, Guilligay, Pflug, Malet, Berger, Crepin, Hart, Lunardi, Nanao, Ruigrok, Cusack (bib101) 2014; 516 Hayden, Belshe, Clover, Hay, Oakes, Soo (bib40) 1989; 321 Kiso, Yamayoshi, Furusawa, Imai, Kawaoka (bib65) 2019 Van Poelvoorde, Saelens, Thomas, Roosens (bib129) 2020; 38 Zhou, Lin, Wang, Halpin, Bera, Stockwell, Barr, Wentworth (bib145) 2014; 52 Du, Nugent, Galvani, Krug, Meyers (bib21) 2020; 11 Lina, Boucher, Osterhaus, Monto, Schutten, Whitley, Nguyen-Van-Tam (bib77) 2018; 12 Gubareva, Fry (bib34) 2020; 221 Taniguchi, Ando, Nobori, Toba, Noshi, Kobayashi, Kawai, Yoshida, Sato, Shishido, Naito, Matsuno, Okamatsu, Sakoda, Kida (bib124) 2019; 9 Wetherall, Trivedi, Zeller, Hodges-Savola, McKimm-Breschkin, Zambon, Hayden (bib135) 2003; 41 Krug, Broni, Bouloy (bib70) 1979; 18 Stevaert, Naesens (bib111) 2016; 36 Parry (bib94) 2005; 331 Hodges, Mishin, De la Cruz, Guo, Nguyen, Fallows, Stevens, Wentworth, Davis, Gubareva (bib47) 2019; 13 Bloom, Gong, Baltimore (bib8) 2010; 328 Poon, Pritlove, Fodor, Brownlee (bib99) 1999; 73 Finberg, Lanno, Anderson, Fleischhackl, van Duijnhoven, Kauffman, Kosoglou, Vingerhoets, Leopold (bib22) 2019; 219 Fry, Goswami, Nahar, Sharmin, Rahman, Gubareva, Azim, Bresee, Luby, Brooks (bib25) 2014; 14 Nakauchi, Ujike, Obuchi, Takashita, Takayama, Ejima, Oba, Konomi, Odagiri, Tashiro, Kageyama (bib89) 2011; 83 Kiso, Lopes, Yamayoshi, Ito, Yamashita, Nakajima, Hasegawa, Neumann, Kawaoka (bib64) 2018; 217 Monto, McKimm-Breschkin, Macken, Hampson, Hay, Klimov, Tashiro, Webster, Aymard, Hayden, Zambon (bib86) 2006; 50 Higashiguchi, Matsumoto, Fujii (bib45) 2018; 23 van der Vries, Stittelaar, van Amerongen, Veldhuis Kroeze, de Waal, Fraaij, Meesters, Luider, van der Nagel, Koch, Vulto, Schutten, Osterhaus (bib128) 2013; 9 Beigel, Nam, Adams, Krafft, Ince, El-Kamary, Sims (bib7) 2019; vol. 167 McKimm-Breschkin, Jiang, Hui, Beigel, Govorkova, Lee (bib82) 2018; 149 Muthuri, Venkatesan, Myles, Leonardi-Bee, Al Khuwaitir, Al Mamun, Anovadiya, Azziz-Baumgartner, Baez, Bassetti, Beovic, Bertisch, Bonmarin, Booy, Borja-Aburto, Burgmann, Cao, Carratala, Denholm, Dominguez, Duarte, Dubnov-Raz, Echavarria, Fanella, Gao, Gerardin, Giannella, Gubbels, Herberg, Iglesias, Hoger, Hu, Islam, Jimenez, Kandeel, Keijzers, Khalili, Knight, Kudo, Kusznierz, Kuzman, Kwan, Amine, Langenegger, Lankarani, Leo, Linko, Liu, Madanat, Mayo-Montero, McGeer, Memish, Metan, Mickiene, Mikic, Mohn, Moradi, Nymadawa, Oliva, Ozkan, Parekh, Paul, Polack, Rath, Rodriguez, Sarrouf, Seale, Sertogullarindan, Siqueira, Skret-Magierlo, Stephan, Talarek, Tang, To, Torres, Torun, Tran, Uyeki, Van Zwol, Vaudry, Vidmar, Yokota, Zarogoulidis, Investigators, Nguyen-Van-Tam (bib87) 2014; 2 Yokoyama, Sakaguchi, Ishibashi, Shishido, Piedra, Sato, Tsuchiya, Uehara (bib143) 2020; 39 Jefferson, Jones, Doshi, Del Mar, Hama, Thompson, Onakpoya, Heneghan (bib57) 2014; 4 Kim, Lew, Williams, Liu, Zhang, Swaminathan, Bischofberger, Chen, Mendel, Tai, Laver, Stevens (bib63) 1997; 119 WHO (bib138) 2012; 87 Yogaratnam, Rito, Kakuda, Fennema, Gupta, Jekle, Mitchell, Boyce, Sahgal, Balaratnam, Chanda, Van Remoortere, Symons, Fry (bib142) 2019; 219 Fodor, Te Velthuis (bib23) 2020; 10 Hay, McCauley (bib39) 2018 Marathe, Wong, Vogel, Garcia-Alcalde, Webster, Webby, Najera, Govorkova (bib78) 2016; 6 Wang, Fan, Salam, Horby, Hayden, Chen, Pan, Zheng, Lu, Guo, Wang, Cao (bib132) 2020; 221 Whitley, Boucher, Lina, Nguyen-Van-Tam, Osterhaus, Schutten, Monto (bib137) 2013; 56 Gubareva, Mishin, Patel, Chesnokov, Nguyen, De La Cruz, Spencer, Campbell, Sinner, Reid, Garten, Katz, Fry, Barnes, Wentworth (bib35) 2019; 24 Chao, Bloom, Kochin, Antia, Longini (bib12) 2012; 9 Lackenby, Hungnes, Dudman, Meijer, Paget, Hay, Zambon (bib74) 2008; 13 Whitley, Laughlin, Carson, Mitha, Tellier, Stich, Elder, Alexander, Dobo, Collis, Sheridan (bib136) 2015; 20 Nakauchi, Takashita, Fujisaki, Shirakura, Ogawa, Morita, Miura, Saito, Watanabe, Odagiri, Kageyama (bib88) 2020; 14 Furuta, Takahashi, Fukuda, Kuno, Kamiyama, Kozaki, Nomura, Egawa, Minami, Watanabe, Narita, Shiraki (bib28) 2002; 46 Patel, Mishin, De La Cruz, Chesnokov, Nguyen, Wilson, Barnes, Kondor, Wentworth, Gubareva (bib96) 2020; 182 Yano, Ochiai, Akachi, Matsumura (bib141) 2020; 73 Rambo-Martin, Keller, Wilson, Nolting, Anderson, Vincent, Bagal, Jang, Neuhaus, Davis, Bowman, Wentworth, Barnes (bib100) 2020; 5 Kawai, Ikematsu, Hirotsu, Maeda, Kawashima, Tanaka, Yamauchi, Kawamura, Matsuura, Nishimura, Iwaki, Kashiwagi (bib62) 2009; 49 Kitano, Matsuzaki, Oka, Baba, Noda, Yoshida, Sato, Kiyota, Mizutare, Yoshida, Sato, Kamimori, Shishido, Naito (bib67) 2020 Takashita, Morita, Ogawa, Nakamura, Fujisaki, Shirakura, Kuwahara, Kishida, Watanabe, Odagiri (bib123) 2018; 9 Trevejo, Asmal, Vingerhoets, Polo, Robertson, Jiang, Kieffer, Leopold (bib126) 2018; 23 Janssen (bib55) 2020 Omoto, Speranzini, Hashimoto, Noshi, Yamaguchi, Kawai, Kawaguchi, Uehara, Shishido, Naito, Cusack (bib92) 2018; 8 Goldhill, Yan, Frise, Zhou, Shelley, Gallego Cortés, Miah, Akinbami, Galiano, Zambon, Lackenby, Barclay (bib31) 2021; 17 Hayden, Sugaya, Hirotsu, Lee, de Jong, Hurt, Ishida, Sekino, Yamada, Portsmouth, Kawaguchi, Shishido, Arai, Tsuchiya, Uehara, Watanabe, Baloxavir Marboxil Investigators (bib44) 2018; 379 Bright, Medina, Xu, Perez-Oronoz, Wallis, Davis, Povinelli, Cox, Klimov (bib9) 2005; 366 Tashiro, McKimm-Breschkin, Saito, Klimov, Macken, Zambon, Hayden, Neuraminidase Inhibitor Susceptibility (bib125) 2009; 14 Chesnokov, Patel, Mishin, De La Cruz, Lollis, Nguyen, Dugan, Wentworth, Gubareva (bib14) 2020; 221 Takashita, Ejima, Ogawa, Fujisaki, Neumann, Furuta, Kawaoka, Tashiro, Odagiri (bib118) 2016; 132 Fukao, Ando, Noshi, Kitano, Noda, Kawai, Yoshida, Sato, Shishido, Naito (bib26) 2019; 14 Takashita (bib115) 2020 Hurt, Ernest, Deng, Iannello, Besselaar, Birch, Buchy, Chittaganpitch, Chiu, Dwyer, Guigon, Harrower, Kei, Kok, Lin, McPhie, Mohd, Olveda, Panayotou, Rawlinson, Scott, Smith, D'Souza, Komadina, Shaw, Kelso, Barr (bib48) 2009; 83 Hurt, Nor'e, McCaw, Fryer, Mosse, McLean, Barr (bib50) 2010; 84 Dobson, Whitley, Pocock, Monto (bib19) 2015; 385 Zhou, Donnelly, Scholes, St George, Hatta, Kawaoka, Wentworth (bib144) 2009; 83 Kaiser, Keene, Hammond, Elliott, Hayden (bib61) 2000; 160 Wang, Zhong, Salam, Tarning, Zhan, Huang, Weng, Bai, Ren, Yamada, Wang, Guo, Fang, Tsutomu, Zou, Li, Gillesen, Castle, Chen, Li, Zhen, Lu, Duan, Guo, Jiang, Cao, Fan, Li, Hayden, Wang, Horby, Cao (bib133) 2020; 62 Plotch, Bouloy, Krug (bib98) 1979; 76 Sato, Takashita, Katayose, Nemoto, Sakai, Fujisaki, Hashimoto, Hosoya (bib104) 2021 Sato, Takashita, Katayose, Nemoto, Sakai, Hashimoto, Hosoya (bib105) 2020; 222 Goldhill, Te Velthuis, Fletcher, Langat, Zambon, Lackenby, Barclay (bib30) 2018; 115 Ando, Noshi, Sato, Ishibashi, Yoshida, Hasegawa, Onishi, Kitano, Oka, Kawai, Yoshida, Sato, Shishido, Naito (bib2) 2021; 76 McKimm-Breschkin (bib81) 2013; 7 (bib90) 2019 Behillil, May, Fourati, Luyt, Chicheportiche, Sonneville, Tandjaoui-Lambiotte, Roux, Guérin, Mayaux, Maury, Ferré, Georger, Voiriot, Enouf, van der Werf, Dessap, de Prost (bib6) 2020; 71 Hayden, Osterhaus, Treanor, Fleming, Aoki, Nicholson, Bohnen, Hirst, Keene, Wightman (bib41) 1997; 337 Hall, Dolin, Gala, Markovitz, Zhang, Madore, Disney, Talpey, Green, Francis (bib36) 1987; 80 Hashimoto, Baba, Inoue, Okane, Hata, Shishido, Naito, Wildum, Omoto (bib38) 2021; 15 Osada, Chon, Phyu, Wagatsuma, Nagata, Kawashima, Sato, Saito, Kodo, Masaki, Asoh, Tsuchihashi, Shirahige, Ono, Shimada, Hamabata, Saito, Saito (bib93) 2021; 188 Takashita, Kiso, Fujisaki, Yokoyama, Nakamura, Shirakura, Sato, Odagiri, Kawaoka, Tashiro (bib122) 2015; 59 WHO (bib139) 2021 Noshi, Kitano, Taniguchi, Yamamoto, Omoto, Baba, Hashimoto, Ishida, Kushima, Hattori, Kawai, Yoshida, Kobayashi, Yoshinaga, Sato, Okamatsu, Sakoda, Kida, Shishido, Naito (bib91) 2018; 160 WHO (bib140) 2021 Takashita, Kawakami, Morita, Ogawa, Fujisaki, Shirakura, Miura, Nakamura, Kishida, Kuwahara, Mitamura, Abe, Ichikawa, Yamazaki, Watanabe, Odagiri (bib120) 2019; 24 Roosenhoff, van der Vries, van der Ince (10.1016/j.antiviral.2021.105158_bib53) 2020; 222 Roosenhoff (10.1016/j.antiviral.2021.105158_bib102) 2018; 13 Bloom (10.1016/j.antiviral.2021.105158_bib8) 2010; 328 Lackenby (10.1016/j.antiviral.2021.105158_bib74) 2008; 13 Sleeman (10.1016/j.antiviral.2021.105158_bib108) 2010; 54 Hayden (10.1016/j.antiviral.2021.105158_bib44) 2018; 379 Watanabe (10.1016/j.antiviral.2021.105158_bib134) 2010; 51 Janssen (10.1016/j.antiviral.2021.105158_bib55) 2020 Koszalka (10.1016/j.antiviral.2021.105158_bib68) 2020; 14 Kim (10.1016/j.antiviral.2021.105158_bib63) 1997; 119 Abed (10.1016/j.antiviral.2021.105158_bib1) 2020; 179 Smee (10.1016/j.antiviral.2021.105158_bib109) 2016; 136 Chan (10.1016/j.antiviral.2021.105158_bib11) 2012; 206 Sato (10.1016/j.antiviral.2021.105158_bib105) 2020; 222 Harada (10.1016/j.antiviral.2021.105158_bib37) 2020; 20 Clark (10.1016/j.antiviral.2021.105158_bib15) 2014; 57 Higashiguchi (10.1016/j.antiviral.2021.105158_bib45) 2018; 23 Tashiro (10.1016/j.antiviral.2021.105158_bib125) 2009; 14 Wang (10.1016/j.antiviral.2021.105158_bib132) 2020; 221 WHO (10.1016/j.antiviral.2021.105158_bib138) 2012; 87 Van Poelvoorde (10.1016/j.antiviral.2021.105158_bib129) 2020; 38 Soh (10.1016/j.antiviral.2021.105158_bib110) 2021 Parry (10.1016/j.antiviral.2021.105158_bib94) 2005; 331 Marathe (10.1016/j.antiviral.2021.105158_bib78) 2016; 6 McKimm-Breschkin (10.1016/j.antiviral.2021.105158_bib80) 2003; 47 Beigel (10.1016/j.antiviral.2021.105158_bib7) 2019; vol. 167 Jefferson (10.1016/j.antiviral.2021.105158_bib57) 2014; 4 Chesnokov (10.1016/j.antiviral.2021.105158_bib14) 2020; 221 Kitano (10.1016/j.antiviral.2021.105158_bib67) 2020 Fukao (10.1016/j.antiviral.2021.105158_bib26) 2019; 14 Takashita (10.1016/j.antiviral.2021.105158_bib121) 2019; 24 Ghedin (10.1016/j.antiviral.2021.105158_bib29) 2012; 206 Fodor (10.1016/j.antiviral.2021.105158_bib23) 2020; 10 Sato (10.1016/j.antiviral.2021.105158_bib104) 2021 Baranovich (10.1016/j.antiviral.2021.105158_bib4) 2013; 87 Poon (10.1016/j.antiviral.2021.105158_bib99) 1999; 73 Mifsud (10.1016/j.antiviral.2021.105158_bib83) 2019; 169 Hashimoto (10.1016/j.antiviral.2021.105158_bib38) 2021; 15 (10.1016/j.antiviral.2021.105158_bib90) 2019 Takashita (10.1016/j.antiviral.2021.105158_bib116) 2020; 180 Ikematsu (10.1016/j.antiviral.2021.105158_bib51) 2020; 383 Dias (10.1016/j.antiviral.2021.105158_bib18) 2009; 458 Lee (10.1016/j.antiviral.2021.105158_bib76) 2020; 16 Deyde (10.1016/j.antiviral.2021.105158_bib17) 2007; vol. 196 Saito (10.1016/j.antiviral.2021.105158_bib103) 2010; 29 Hurt (10.1016/j.antiviral.2021.105158_bib49) 2012; 206 Jones (10.1016/j.antiviral.2021.105158_bib59) 2021; 76 Hurt (10.1016/j.antiviral.2021.105158_bib48) 2009; 83 Taniguchi (10.1016/j.antiviral.2021.105158_bib124) 2019; 9 Rambo-Martin (10.1016/j.antiviral.2021.105158_bib100) 2020; 5 Lee (10.1016/j.antiviral.2021.105158_bib75) 2021; 17 Deyde (10.1016/j.antiviral.2021.105158_bib16) 2010; 54 Kwon (10.1016/j.antiviral.2021.105158_bib72) 2018; 99 van der Vries (10.1016/j.antiviral.2021.105158_bib128) 2013; 9 Takahashi (10.1016/j.antiviral.2021.105158_bib114) 2003; 14 Jefferson (10.1016/j.antiviral.2021.105158_bib56) 2011; 342 Ison (10.1016/j.antiviral.2021.105158_bib54) 2020; 20 Takashita (10.1016/j.antiviral.2021.105158_bib118) 2016; 132 Hay (10.1016/j.antiviral.2021.105158_bib39) 2018 Lackenby (10.1016/j.antiviral.2021.105158_bib73) 2018; 157 Du (10.1016/j.antiviral.2021.105158_bib21) 2020; 11 Takashita (10.1016/j.antiviral.2021.105158_bib122) 2015; 59 Uehara (10.1016/j.antiviral.2021.105158_bib127) 2020; 221 Hurt (10.1016/j.antiviral.2021.105158_bib50) 2010; 84 Dobson (10.1016/j.antiviral.2021.105158_bib19) 2015; 385 Doshi (10.1016/j.antiviral.2021.105158_bib20) 2013; 346 Furuta (10.1016/j.antiviral.2021.105158_bib28) 2002; 46 Hayden (10.1016/j.antiviral.2021.105158_bib42) 2019; 32 Gubareva (10.1016/j.antiviral.2021.105158_bib35) 2019; 24 Byrn (10.1016/j.antiviral.2021.105158_bib10) 2015; 59 Jones (10.1016/j.antiviral.2021.105158_bib58) 2020; 117 Hayden (10.1016/j.antiviral.2021.105158_bib41) 1997; 337 Nakauchi (10.1016/j.antiviral.2021.105158_bib88) 2020; 14 Kumar (10.1016/j.antiviral.2021.105158_bib71) 2020 Omoto (10.1016/j.antiviral.2021.105158_bib92) 2018; 8 Fukao (10.1016/j.antiviral.2021.105158_bib27) 2019; 74 von Itzstein (10.1016/j.antiviral.2021.105158_bib131) 1993; 363 Behillil (10.1016/j.antiviral.2021.105158_bib6) 2020; 71 Goldhill (10.1016/j.antiviral.2021.105158_bib30) 2018; 115 Fry (10.1016/j.antiviral.2021.105158_bib25) 2014; 14 Muthuri (10.1016/j.antiviral.2021.105158_bib87) 2014; 2 Mishin (10.1016/j.antiviral.2021.105158_bib85) 2019; 25 Mira (10.1016/j.antiviral.2021.105158_bib84) 2020 Takashita (10.1016/j.antiviral.2021.105158_bib117) 2020; 175 Yano (10.1016/j.antiviral.2021.105158_bib141) 2020; 73 Yokoyama (10.1016/j.antiviral.2021.105158_bib143) 2020; 39 WHO (10.1016/j.antiviral.2021.105158_bib140) 2021 Baker (10.1016/j.antiviral.2021.105158_bib3) 2020; 39 Takada (10.1016/j.antiviral.2021.105158_bib113) 2019; 4 Patel (10.1016/j.antiviral.2021.105158_bib96) 2020; 182 Osada (10.1016/j.antiviral.2021.105158_bib93) 2021; 188 Wetherall (10.1016/j.antiviral.2021.105158_bib135) 2003; 41 Plotch (10.1016/j.antiviral.2021.105158_bib98) 1979; 76 Goldhill (10.1016/j.antiviral.2021.105158_bib31) 2021; 17 Jorquera (10.1016/j.antiviral.2021.105158_bib60) 2019; 9 Takashita (10.1016/j.antiviral.2021.105158_bib119) 2019; 25 WHO (10.1016/j.antiviral.2021.105158_bib139) 2021 Hirotsu (10.1016/j.antiviral.2021.105158_bib46) 2020; 71 Gravenstein (10.1016/j.antiviral.2021.105158_bib33) 2005; 6 Venkatesan (10.1016/j.antiviral.2021.105158_bib130) 2017; 64 Kiso (10.1016/j.antiviral.2021.105158_bib64) 2018; 217 Finberg (10.1016/j.antiviral.2021.105158_bib22) 2019; 219 Hall (10.1016/j.antiviral.2021.105158_bib36) 1987; 80 Krug (10.1016/j.antiviral.2021.105158_bib70) 1979; 18 Kiso (10.1016/j.antiviral.2021.105158_bib65) 2019 Nakauchi (10.1016/j.antiviral.2021.105158_bib89) 2011; 83 Wang (10.1016/j.antiviral.2021.105158_bib133) 2020; 62 Hayden (10.1016/j.antiviral.2021.105158_bib40) 1989; 321 Koszalka (10.1016/j.antiviral.2021.105158_bib69) 2019; 164 Bright (10.1016/j.antiviral.2021.105158_bib9) 2005; 366 Lina (10.1016/j.antiviral.2021.105158_bib77) 2018; 12 Reich (10.1016/j.antiviral.2021.105158_bib101) 2014; 516 Takashita (10.1016/j.antiviral.2021.105158_bib123) 2018; 9 Takashita (10.1016/j.antiviral.2021.105158_bib115) 2020 Matrosovich (10.1016/j.antiviral.2021.105158_bib79) 2003; 77 Noshi (10.1016/j.antiviral.2021.105158_bib91) 2018; 160 Patel (10.1016/j.antiviral.2021.105158_bib95) 2021; 188 Zhou (10.1016/j.antiviral.2021.105158_bib144) 2009; 83 Kawai (10.1016/j.antiviral.2021.105158_bib62) 2009; 49 Takashita (10.1016/j.antiviral.2021.105158_bib120) 2019; 24 Shionogi (10.1016/j.antiviral.2021.105158_bib107) 2019 Whitley (10.1016/j.antiviral.2021.105158_bib136) 2015; 20 Monto (10.1016/j.antiviral.2021.105158_bib86) 2006; 50 Barrett (10.1016/j.antiviral.2021.105158_bib5) 2011; 6 McKimm-Breschkin (10.1016/j.antiviral.2021.105158_bib81) 2013; 7 Stevaert (10.1016/j.antiviral.2021.105158_bib111) 2016; 36 Checkmahomed (10.1016/j.antiviral.2021.105158_bib13) 2020; 221 Sweet (10.1016/j.antiviral.2021.105158_bib112) 1991; 164 Kaiser (10.1016/j.antiviral.2021.105158_bib61) 2000; 160 Zhou (10.1016/j.antiviral.2021.105158_bib145) 2014; 52 Chao (10.1016/j.antiviral.2021.105158_bib12) 2012; 9 Hodges (10.1016/j.antiviral.2021.105158_bib47) 2019; 13 Ando (10.1016/j.antiviral.2021.105158_bib2) 2021; 76 Whitley (10.1016/j.antiviral.2021.105158_bib137) 2013; 56 Frise (10.1016/j.antiviral.2021.105158_bib24) 2019 Pflug (10.1016/j.antiviral.2021.105158_bib97) 2014; 516 Yogaratnam (10.1016/j.antiviral.2021.105158_bib142) 2019; 219 Hayden (10.1016/j.antiviral.2021.105158_bib43) 1991; vol. 35 Trevejo (10.1016/j.antiviral.2021.105158_bib126) 2018; 23 Sheu (10.1016/j.antiviral.2021.105158_bib106) 2011; 203 McKimm-Breschkin (10.1016/j.antiviral.2021.105158_bib82) 2018; 149 Kiso (10.1016/j.antiviral.2021.105158_bib66) 2020; 221 Govorkova (10.1016/j.antiviral.2021.105158_bib32) 2010; 84 Gubareva (10.1016/j.antiviral.2021.105158_bib34) 2020; 221 Imai (10.1016/j.antiviral.2021.105158_bib52) 2020; 5 |
| References_xml | – volume: 9 start-page: 2676 year: 2019 ident: bib60 article-title: Insights into the antigenic advancement of influenza A(H3N2) viruses, 2011-2018 publication-title: Sci. Rep. – volume: 13 year: 2008 ident: bib74 article-title: Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe publication-title: Euro Surveill. – volume: 76 start-page: 1618 year: 1979 end-page: 1622 ident: bib98 article-title: Transfer of 5'-terminal cap of globin mRNA to influenza viral complementary RNA during transcription in vitro publication-title: Proc. Natl. Acad. Sci. U. S. A. – volume: 54 start-page: 2517 year: 2010 end-page: 2524 ident: bib108 article-title: In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses publication-title: Antimicrob. Agents Chemother. – year: 2021 ident: bib139 article-title: Laboratory Methodologies for Testing the Antiviral Susceptibility of Influenza Viruses: Neuraminidase Inhibitor (NAI) – year: 2021 ident: bib110 article-title: Comprehensive profiling of mutations to influenza virus PB2 that confer resistance to the cap-binding inhibitor pimodivir publication-title: Viruses 13 – volume: 379 start-page: 913 year: 2018 end-page: 923 ident: bib44 article-title: Baloxavir marboxil for uncomplicated influenza in adults and adolescents publication-title: N. Engl. J. Med. – volume: 71 start-page: 971 year: 2020 end-page: 981 ident: bib46 article-title: Baloxavir marboxil in Japanese pediatric patients with influenza: safety and clinical and virologic outcomes publication-title: Clin. Infect. Dis. – volume: 99 start-page: 292 year: 2018 end-page: 302 ident: bib72 article-title: An I436N substitution confers resistance of influenza A(H1N1)pdm09 viruses to multiple neuraminidase inhibitors without affecting viral fitness publication-title: J. Gen. Virol. – volume: 59 start-page: 2607 year: 2015 end-page: 2617 ident: bib122 article-title: Characterization of a large cluster of influenza A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013-2014 influenza season in Japan publication-title: Antimicrob. Agents Chemother. – volume: 74 start-page: 654 year: 2019 end-page: 662 ident: bib27 article-title: Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection publication-title: J. Antimicrob. Chemother. – volume: 164 start-page: 969 year: 1991 end-page: 972 ident: bib112 article-title: Virulence of rimantadine-resistant human influenza A (H3N2) viruses in ferrets publication-title: J. Infect. Dis. – volume: 221 start-page: 337 year: 2020 end-page: 339 ident: bib34 article-title: Baloxavir and treatment-emergent resistance: public health insights and next steps publication-title: J. Infect. Dis. – year: 2018 ident: bib39 article-title: The WHO global influenza surveillance and response system (GISRS)-A future perspective publication-title: Influenza Other Respir Viruses – volume: 383 start-page: 309 year: 2020 end-page: 320 ident: bib51 article-title: Baloxavir marboxil for prophylaxis against influenza in household contacts publication-title: N. Engl. J. Med. – volume: 221 start-page: 1699 year: 2020 end-page: 1702 ident: bib66 article-title: Baloxavir marboxil treatment of nude mice infected with influenza A virus publication-title: J. Infect. Dis. – year: 2019 ident: bib107 article-title: Shionogi Provides Update on Japanese Association for Infectious Diseases Statement and the Revised Guidelines of the Japanese Pediatric Society for the Treatment of Influenza – volume: 219 start-page: 1026 year: 2019 end-page: 1034 ident: bib22 article-title: Phase 2b study of pimodivir (JNJ-63623872) as monotherapy or in combination with oseltamivir for treatment of acute uncomplicated seasonal influenza A: TOPAZ trial publication-title: J. Infect. Dis. – volume: 7 start-page: 25 year: 2013 end-page: 36 ident: bib81 article-title: Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance publication-title: Influenza Other Respir Viruses – volume: 83 start-page: 10309 year: 2009 end-page: 10313 ident: bib144 article-title: Single-reaction genomic amplification accelerates sequencing and vaccine production for classical and Swine origin human influenza a viruses publication-title: J. Virol. – volume: 52 start-page: 1330 year: 2014 end-page: 1337 ident: bib145 article-title: Universal influenza B virus genomic amplification facilitates sequencing, diagnostics, and reverse genetics publication-title: J. Clin. Microbiol. – year: 2020 ident: bib71 article-title: Combining Baloxavir with Standard-Of-Care (SoC) Neuraminidase Inhibitor (NAI) in Patients Hospitalised with Severe Influenza: Results from the Global Randomised Phase 3 FLAGSTONE Study ESWI – volume: 9 start-page: 648 year: 2012 end-page: 656 ident: bib12 article-title: The global spread of drug-resistant influenza publication-title: J. R. Soc. Interface – volume: 206 start-page: 148 year: 2012 end-page: 157 ident: bib49 article-title: Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia publication-title: J. Infect. Dis. – volume: 363 start-page: 418 year: 1993 end-page: 423 ident: bib131 article-title: Rational design of potent sialidase-based inhibitors of influenza virus replication publication-title: Nature – volume: 41 start-page: 742 year: 2003 end-page: 750 ident: bib135 article-title: Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network publication-title: J. Clin. Microbiol. – volume: 76 start-page: 189 year: 2021 end-page: 198 ident: bib2 article-title: Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection publication-title: J. Antimicrob. Chemother. – volume: 51 start-page: 1167 year: 2010 end-page: 1175 ident: bib134 article-title: Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial publication-title: Clin. Infect. Dis. – volume: 206 start-page: 1504 year: 2012 end-page: 1511 ident: bib29 article-title: Presence of oseltamivir-resistant pandemic A/H1N1 minor variants before drug therapy with subsequent selection and transmission publication-title: J. Infect. Dis. – volume: 18 start-page: 329 year: 1979 end-page: 334 ident: bib70 article-title: Are the 5' ends of influenza viral mRNAs synthesized in vivo donated by host mRNAs? publication-title: Cell – volume: 2 start-page: 395 year: 2014 end-page: 404 ident: bib87 article-title: Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data publication-title: Lancet Respir Med – volume: 73 start-page: 3473 year: 1999 end-page: 3476 ident: bib99 article-title: Direct evidence that the poly(A) tail of influenza A virus mRNA is synthesized by reiterative copying of a U track in the virion RNA template publication-title: J. Virol. – volume: 80 start-page: 275 year: 1987 end-page: 282 ident: bib36 article-title: Children with influenza A infection: treatment with rimantadine publication-title: Pediatrics – year: 2020 ident: bib84 article-title: Low Rates of Antiviral Resistance in Hospitalised Patients Treated with Baloxavir Plus Standard-Of-Care Neuraminidase Inhibitors (NAIs) or Placebo Plus NAIs: Genotypic Analysis of the Phase 3 FLAGSTONE Study – volume: 71 start-page: 1089 year: 2020 end-page: 1091 ident: bib6 article-title: Oseltamivir resistance in severe influenza A(H1N1)pdm09 pneumonia and acute respiratory distress syndrome: a French multicenter observational cohort study publication-title: Clin. Infect. Dis. – volume: 328 start-page: 1272 year: 2010 end-page: 1275 ident: bib8 article-title: Permissive secondary mutations enable the evolution of influenza oseltamivir resistance publication-title: Science – volume: 54 start-page: 1102 year: 2010 end-page: 1110 ident: bib16 article-title: Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing publication-title: Antimicrob. Agents Chemother. – volume: 11 start-page: 2750 year: 2020 ident: bib21 article-title: Modeling mitigation of influenza epidemics by baloxavir publication-title: Nat. Commun. – volume: vol. 167 start-page: 45 year: 2019 end-page: 67 ident: bib7 publication-title: Advances in Respiratory Virus Therapeutics - A Meeting Report from the 6th Isirv Antiviral Group Conference Antiviral Res – volume: 117 start-page: 8593 year: 2020 end-page: 8601 ident: bib58 article-title: Influenza A and B viruses with reduced baloxavir susceptibility display attenuated in vitro fitness but retain ferret transmissibility publication-title: Proc. Natl. Acad. Sci. U. S. A. – volume: 206 start-page: 1359 year: 2012 end-page: 1366 ident: bib11 article-title: Determinants of antiviral effectiveness in influenza virus A subtype H5N1 publication-title: J. Infect. Dis. – volume: 180 start-page: 104828 year: 2020 ident: bib116 article-title: Influenza A(H1N1)pdm09 virus exhibiting reduced susceptibility to baloxavir due to a PA E23K substitution detected from a child without baloxavir treatment publication-title: Antivir. Res. – volume: 23 start-page: 157 year: 2018 end-page: 165 ident: bib45 article-title: A meta-analysis of laninamivir octanoate for treatment and prophylaxis of influenza publication-title: Antivir. Ther. – volume: 6 start-page: 359 year: 2005 end-page: 366 ident: bib33 article-title: Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long-term care population publication-title: J. Am. Med. Dir. Assoc. – volume: 188 start-page: 105035 year: 2021 ident: bib95 article-title: Susceptibility of widely diverse influenza a viruses to PB2 polymerase inhibitor pimodivir publication-title: Antivir. Res. – volume: 217 start-page: 887 year: 2018 end-page: 896 ident: bib64 article-title: Combination therapy with neuraminidase and polymerase inhibitors in nude mice infected with influenza virus publication-title: J. Infect. Dis. – volume: 23 start-page: 335 year: 2018 end-page: 344 ident: bib126 article-title: Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study publication-title: Antivir. Ther. – year: 2019 ident: bib65 article-title: Treatment of highly pathogenic H7N9 virus-infected mice with baloxavir marboxil publication-title: Viruses 11 – volume: 20 start-page: 478 year: 2020 ident: bib37 article-title: Successful treatment with baloxavir marboxil of a patient with peramivir-resistant influenza A/H3N2 with a dual E119D/R292K substitution after allogeneic hematopoietic cell transplantation: a case report publication-title: BMC Infect. Dis. – volume: 16 year: 2020 ident: bib76 article-title: Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission publication-title: PLoS Pathog. – year: 2021 ident: bib104 article-title: Detection of variants with reduced baloxavir marboxil and oseltamivir susceptibility in children with influenza A during the 2019-2020 influenza season publication-title: J. Infect. Dis. – volume: 337 start-page: 874 year: 1997 end-page: 880 ident: bib41 article-title: Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group publication-title: N. Engl. J. Med. – volume: 25 start-page: 1969 year: 2019 end-page: 1972 ident: bib85 article-title: Susceptibility of influenza A, B, C, and D viruses to baloxavir(1) publication-title: Emerg. Infect. Dis. – volume: 83 start-page: 1121 year: 2011 end-page: 1127 ident: bib89 article-title: Rapid discrimination of oseltamivir-resistant 275Y and -susceptible 275H substitutions in the neuraminidase gene of pandemic influenza A/H1N1 2009 virus by duplex one-step RT-PCR assay publication-title: J. Med. Virol. – volume: 76 start-page: 957 year: 2021 end-page: 960 ident: bib59 article-title: Multiple polymerase acidic (PA) I38X substitutions in influenza A(H1N1)pdm09 virus permit polymerase activity and cause reduced baloxavir inhibition publication-title: J. Antimicrob. Chemother. – volume: 4 year: 2014 ident: bib57 article-title: Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports publication-title: BMJ open – volume: 157 start-page: 38 year: 2018 end-page: 46 ident: bib73 article-title: Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017 publication-title: Antivir. Res. – volume: 64 start-page: 1328 year: 2017 end-page: 1334 ident: bib130 article-title: Impact of outpatient neuraminidase inhibitor treatment in patients infected with influenza A(H1N1)pdm09 at high risk of hospitalization: an individual participant data metaanalysis publication-title: Clin. Infect. Dis. – volume: 366 start-page: 1175 year: 2005 end-page: 1181 ident: bib9 article-title: Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern publication-title: Lancet – volume: 39 start-page: 700 year: 2020 end-page: 705 ident: bib3 article-title: Baloxavir marboxil single-dose treatment in influenza-infected children: a randomized, double-blind, active controlled phase 3 safety and efficacy trial (miniSTONE-2) publication-title: Pediatr. Infect. Dis. J. – volume: 20 start-page: 709 year: 2015 end-page: 719 ident: bib136 article-title: Single dose peramivir for the treatment of acute seasonal influenza: integrated analysis of efficacy and safety from two placebo-controlled trials publication-title: Antivir. Ther. – volume: 24 year: 2019 ident: bib35 article-title: Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons publication-title: Euro Surveill. – volume: 14 start-page: 109 year: 2014 end-page: 118 ident: bib25 article-title: Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial publication-title: Lancet Infect. Dis. – volume: 6 start-page: 26742 year: 2016 ident: bib78 article-title: Combinations of oseltamivir and T-705 Extend the treatment window for highly pathogenic influenza A(H5N1) virus infection in mice publication-title: Sci. Rep. – volume: 24 year: 2019 ident: bib121 article-title: Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019 publication-title: Euro Surveill. – volume: 164 start-page: 91 year: 2019 end-page: 96 ident: bib69 article-title: Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012-2018 publication-title: Antivir. Res. – volume: vol. 196 start-page: 249 year: 2007 end-page: 257 ident: bib17 publication-title: Surveillance of Resistance to Adamantanes Among Influenza A(H3N2) and A(H1N1) Viruses Isolated Worldwide – volume: 175 start-page: 104718 year: 2020 ident: bib117 article-title: Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018 publication-title: Antivir. Res. – volume: 24 year: 2019 ident: bib120 article-title: Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018 publication-title: Euro Surveill. – volume: 221 start-page: 367 year: 2020 end-page: 371 ident: bib14 article-title: Replicative fitness of seasonal influenza A viruses with decreased susceptibility to baloxavir publication-title: J. Infect. Dis. – volume: 59 start-page: 1569 year: 2015 end-page: 1582 ident: bib10 article-title: Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit publication-title: Antimicrob. Agents Chemother. – volume: 13 start-page: 522 year: 2019 end-page: 527 ident: bib47 article-title: Detection of oseltamivir-resistant zoonotic and animal influenza A viruses using the rapid influenza antiviral resistance test publication-title: Influenza Other Respir Viruses – volume: 10 year: 2020 ident: bib23 article-title: Structure and function of the influenza virus transcription and replication machinery publication-title: Cold Spring Harbor perspectives in medicine – volume: 516 start-page: 361 year: 2014 end-page: 366 ident: bib101 article-title: Structural insight into cap-snatching and RNA synthesis by influenza polymerase publication-title: Nature – volume: 182 start-page: 104906 year: 2020 ident: bib96 article-title: Detection of baloxavir resistant influenza A viruses using next generation sequencing and pyrosequencing methods publication-title: Antivir. Res. – volume: 169 start-page: 104545 year: 2019 ident: bib83 article-title: Antivirals targeting the polymerase complex of influenza viruses publication-title: Antivir. Res. – volume: 219 start-page: 177 year: 2019 end-page: 185 ident: bib142 article-title: Antiviral activity, safety, and pharmacokinetics of AL-794, a novel oral influenza endonuclease inhibitor: results of an influenza human challenge study publication-title: J. Infect. Dis. – volume: 56 start-page: 1197 year: 2013 end-page: 1205 ident: bib137 article-title: Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the influenza resistance information study (IRIS) publication-title: Clin. Infect. Dis. – volume: 62 start-page: 103125 year: 2020 ident: bib133 article-title: Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza publication-title: EBioMedicine – volume: 29 start-page: 898 year: 2010 end-page: 904 ident: bib103 article-title: Reduced effectiveness of oseltamivir in children infected with oseltamivir-resistant influenza A (H1N1) viruses with His275Tyr mutation publication-title: Pediatr. Infect. Dis. J. – volume: 9 year: 2013 ident: bib128 article-title: Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferrets publication-title: PLoS Pathog. – volume: 15 start-page: 389 year: 2021 end-page: 395 ident: bib38 article-title: Comprehensive assessment of amino acid substitutions in the trimeric RNA polymerase complex of influenza A virus detected in clinical trials of baloxavir marboxil publication-title: Influenza Other Respir Viruses – volume: 5 year: 2020 ident: bib100 article-title: Influenza A virus field surveillance at a swine-human interface publication-title: mSphere – volume: 221 start-page: 63 year: 2020 end-page: 70 ident: bib13 article-title: Impact of the baloxavir-resistant polymerase acid I38T substitution on the fitness of contemporary influenza A(H1N1)pdm09 and A(H3N2) strains publication-title: J. Infect. Dis. – volume: 119 start-page: 681 year: 1997 end-page: 690 ident: bib63 article-title: Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity publication-title: J. Am. Chem. Soc. – volume: 221 start-page: 1688 year: 2020 end-page: 1698 ident: bib132 article-title: Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection publication-title: J. Infect. Dis. – volume: 14 start-page: 235 year: 2003 end-page: 241 ident: bib114 article-title: In vitro and in vivo activities of T-705 and oseltamivir against influenza virus publication-title: Antivir. Chem. Chemother. – volume: 179 start-page: 104807 year: 2020 ident: bib1 article-title: Characterization of contemporary influenza B recombinant viruses harboring mutations of reduced susceptibility to baloxavir marboxil, in vitro and in mice publication-title: Antivir. Res. – year: 2020 ident: bib55 article-title: Janssen to Discontinue Pimodivir Influenza Development Program – volume: 342 start-page: c7258 year: 2011 ident: bib56 article-title: Ensuring safe and effective drugs: who can do what it takes? publication-title: Bmj – volume: 13 year: 2018 ident: bib102 article-title: Influenza A/H3N2 virus infection in immunocompromised ferrets and emergence of antiviral resistance publication-title: PloS One – volume: 222 start-page: 121 year: 2020 end-page: 125 ident: bib105 article-title: Detection of variants with reduced baloxavir marboxil susceptibility after treatment of children with influenza A during the 2018-2019 influenza season publication-title: J. Infect. Dis. – volume: 57 start-page: 6668 year: 2014 end-page: 6678 ident: bib15 article-title: Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2 publication-title: J. Med. Chem. – volume: 14 start-page: 436 year: 2020 end-page: 443 ident: bib88 article-title: Rapid detection of an I38T amino acid substitution in influenza polymerase acidic subunit associated with reduced susceptibility to baloxavir marboxil publication-title: Influenza Other Respir Viruses – volume: 221 start-page: 346 year: 2020 end-page: 355 ident: bib127 article-title: Treatment-emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza publication-title: J. Infect. Dis. – volume: 38 start-page: 360 year: 2020 end-page: 367 ident: bib129 article-title: Next-generation sequencing: an eye-Opener for the surveillance of antiviral resistance in influenza publication-title: Trends Biotechnol. – volume: 8 start-page: 9633 year: 2018 ident: bib92 article-title: Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil publication-title: Sci. Rep. – volume: 46 start-page: 977 year: 2002 end-page: 981 ident: bib28 article-title: In vitro and in vivo activities of anti-influenza virus compound T-705 publication-title: Antimicrob. Agents Chemother. – year: 2019 ident: bib90 article-title: Antiviral Resistance Surveillance in Japan 2018/2019 Influenza Season – volume: 25 start-page: 2108 year: 2019 end-page: 2111 ident: bib119 article-title: Human-to-Human transmission of influenza A(H3N2) virus with reduced susceptibility to baloxavir, Japan, february 2019 publication-title: Emerg. Infect. Dis. – volume: 49 start-page: 1828 year: 2009 end-page: 1835 ident: bib62 article-title: Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons publication-title: Clin. Infect. Dis. – volume: 5 start-page: 27 year: 2020 end-page: 33 ident: bib52 article-title: Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets publication-title: Nature microbiology – volume: 39 start-page: 706 year: 2020 end-page: 712 ident: bib143 article-title: Baloxavir marboxil 2% Granules in Japanese children with influenza: an open-label phase 3 study publication-title: Pediatr. Infect. Dis. J. – volume: 17 year: 2021 ident: bib75 article-title: Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model publication-title: PLoS Pathog. – volume: 32 start-page: 176 year: 2019 end-page: 186 ident: bib42 article-title: Influenza virus polymerase inhibitors in clinical development publication-title: Curr. Opin. Infect. Dis. – volume: 222 start-page: 957 year: 2020 end-page: 961 ident: bib53 article-title: Treatment-emergent influenza virus polymerase acidic substitutions independent of those at I38 associated with reduced baloxavir susceptibility and virus rebound in trials of baloxavir marboxil publication-title: J. Infect. Dis. – volume: 136 start-page: 45 year: 2016 end-page: 50 ident: bib109 article-title: Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice publication-title: Antivir. Res. – volume: 149 start-page: 118 year: 2018 end-page: 142 ident: bib82 article-title: Prevention and treatment of respiratory viral infections: presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference publication-title: Antivir. Res. – volume: 87 start-page: 3741 year: 2013 end-page: 3751 ident: bib4 article-title: T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro publication-title: J. Virol. – volume: 84 start-page: 9427 year: 2010 end-page: 9438 ident: bib50 article-title: Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model publication-title: J. Virol. – volume: 188 start-page: 105036 year: 2021 ident: bib93 article-title: Development of cycling probe based real-time PCR methodology for influenza A viruses possessing the PA/I38T amino acid substitution associated with reduced baloxavir susceptibility publication-title: Antivir. Res. – volume: 12 start-page: 267 year: 2018 end-page: 278 ident: bib77 article-title: Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study publication-title: Influenza Other Respir Viruses – volume: 9 start-page: 3466 year: 2019 ident: bib124 article-title: Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil publication-title: Sci. Rep. – volume: 73 start-page: 383 year: 2020 end-page: 385 ident: bib141 article-title: Polymerase acidic subunit I38T mutant influenza A(H3N2) virus isolated from a pediatric patient without prior baloxavir marboxil treatment in mie prefecture (November 2018) publication-title: Jpn. J. Infect. Dis. – volume: 458 start-page: 914 year: 2009 end-page: 918 ident: bib18 article-title: The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit publication-title: Nature – start-page: 10857 year: 2019 ident: bib24 article-title: Baloxavir Reduces Respiratory Droplet Transmission of Influenza A Virus in Ferrets, Options X for the Control of Influenza – year: 2020 ident: bib67 article-title: The antiviral effects of baloxavir marboxil against influenza A virus infection in ferrets publication-title: Influenza Other Respir Viruses – volume: 385 start-page: 1729 year: 2015 end-page: 1737 ident: bib19 article-title: Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials publication-title: Lancet – volume: 84 start-page: 8042 year: 2010 end-page: 8050 ident: bib32 article-title: Competitive fitness of oseltamivir-sensitive and -resistant highly pathogenic H5N1 influenza viruses in a ferret model publication-title: J. Virol. – volume: 321 start-page: 1696 year: 1989 end-page: 1702 ident: bib40 article-title: Emergence and apparent transmission of rimantadine-resistant influenza publication-title: A virus in families – volume: 77 start-page: 8418 year: 2003 end-page: 8425 ident: bib79 article-title: Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors publication-title: J. Virol. – volume: 115 start-page: 11613 year: 2018 end-page: 11618 ident: bib30 article-title: The mechanism of resistance to favipiravir in influenza publication-title: Proc. Natl. Acad. Sci. U. S. A. – volume: 17 year: 2021 ident: bib31 article-title: Favipiravir-resistant influenza A virus shows potential for transmission publication-title: PLoS Pathog. – volume: 6 year: 2011 ident: bib5 article-title: Real time enzyme inhibition assays provide insights into differences in binding of neuraminidase inhibitors to wild type and mutant influenza viruses publication-title: PloS One – volume: 83 start-page: 90 year: 2009 end-page: 93 ident: bib48 article-title: Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, south East Asia and South Africa publication-title: Antivir. Res. – volume: 4 start-page: 1268 year: 2019 end-page: 1273 ident: bib113 article-title: A humanized MDCK cell line for the efficient isolation and propagation of human influenza viruses publication-title: Nature microbiology – volume: 14 start-page: 751 year: 2009 end-page: 761 ident: bib125 article-title: Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007 publication-title: Antivir. Ther. – volume: 132 start-page: 170 year: 2016 end-page: 177 ident: bib118 article-title: Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir publication-title: Antivir. Res. – volume: 50 start-page: 2395 year: 2006 end-page: 2402 ident: bib86 article-title: Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use publication-title: Antimicrob. Agents Chemother. – volume: 47 start-page: 2264 year: 2003 end-page: 2272 ident: bib80 article-title: Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir publication-title: Antimicrob. Agents Chemother. – volume: 20 start-page: 1204 year: 2020 end-page: 1214 ident: bib54 article-title: Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial publication-title: Lancet Infect. Dis. – year: 2020 ident: bib115 article-title: Influenza polymerase inhibitors: mechanisms of action and resistance publication-title: Cold Spring Harbor perspectives in medicine – volume: 331 start-page: 10 year: 2005 ident: bib94 article-title: Use of antiviral drug in poultry is blamed for drug resistant strains of avian flu publication-title: Bmj – volume: 36 start-page: 1127 year: 2016 end-page: 1173 ident: bib111 article-title: The influenza virus polymerase complex: an update on its structure, functions, and significance for antiviral drug design publication-title: Med. Res. Rev. – volume: 9 start-page: 3026 year: 2018 ident: bib123 article-title: Susceptibility of influenza viruses to the novel cap-dependent endonuclease inhibitor baloxavir marboxil publication-title: Front. Microbiol. – year: 2021 ident: bib140 article-title: Laboratory Methodologies for Testing the Antiviral Susceptibility of Influenza Viruses: Polymerase Acidic (PA) Inhibitor – volume: 203 start-page: 13 year: 2011 end-page: 17 ident: bib106 article-title: Dual resistance to adamantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008-2010 publication-title: J. Infect. Dis. – volume: 14 year: 2019 ident: bib26 article-title: Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models publication-title: PloS One – volume: 14 start-page: 460 year: 2020 end-page: 464 ident: bib68 article-title: A rapid pyrosequencing assay for the molecular detection of influenza viruses with reduced baloxavir susceptibility due to PA/I38X amino acid substitutions publication-title: Influenza Other Respir Viruses – volume: 346 start-page: f2865 year: 2013 ident: bib20 article-title: Restoring invisible and abandoned trials: a call for people to publish the findings publication-title: Bmj – volume: 516 start-page: 355 year: 2014 end-page: 360 ident: bib97 article-title: Structure of influenza A polymerase bound to the viral RNA promoter publication-title: Nature – volume: 160 start-page: 3234 year: 2000 end-page: 3240 ident: bib61 article-title: Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults publication-title: Arch. Intern. Med. – volume: vol. 35 start-page: 1741 year: 1991 end-page: 1747 ident: bib43 publication-title: Recovery of Drug-Resistant Influenza A Virus during Therapeutic Use of Rimantadine – volume: 160 start-page: 109 year: 2018 end-page: 117 ident: bib91 article-title: In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit publication-title: Antivir. Res. – volume: 87 start-page: 369 year: 2012 end-page: 374 ident: bib138 article-title: Meetings of the WHO working group on surveillance of influenza antiviral susceptibility - Geneva, November 2011 and June 2012 publication-title: Wkly. Epidemiol. Rec. – volume: 13 year: 2008 ident: 10.1016/j.antiviral.2021.105158_bib74 article-title: Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe publication-title: Euro Surveill. doi: 10.2807/ese.13.05.08026-en – volume: 14 start-page: 235 year: 2003 ident: 10.1016/j.antiviral.2021.105158_bib114 article-title: In vitro and in vivo activities of T-705 and oseltamivir against influenza virus publication-title: Antivir. Chem. Chemother. doi: 10.1177/095632020301400502 – volume: 62 start-page: 103125 year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib133 article-title: Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza publication-title: EBioMedicine doi: 10.1016/j.ebiom.2020.103125 – volume: 36 start-page: 1127 year: 2016 ident: 10.1016/j.antiviral.2021.105158_bib111 article-title: The influenza virus polymerase complex: an update on its structure, functions, and significance for antiviral drug design publication-title: Med. Res. Rev. doi: 10.1002/med.21401 – volume: 221 start-page: 367 year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib14 article-title: Replicative fitness of seasonal influenza A viruses with decreased susceptibility to baloxavir publication-title: J. Infect. Dis. – volume: 117 start-page: 8593 year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib58 article-title: Influenza A and B viruses with reduced baloxavir susceptibility display attenuated in vitro fitness but retain ferret transmissibility publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.1916825117 – volume: 9 start-page: 3026 year: 2018 ident: 10.1016/j.antiviral.2021.105158_bib123 article-title: Susceptibility of influenza viruses to the novel cap-dependent endonuclease inhibitor baloxavir marboxil publication-title: Front. Microbiol. doi: 10.3389/fmicb.2018.03026 – volume: 84 start-page: 9427 year: 2010 ident: 10.1016/j.antiviral.2021.105158_bib50 article-title: Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model publication-title: J. Virol. doi: 10.1128/JVI.00373-10 – volume: 17 year: 2021 ident: 10.1016/j.antiviral.2021.105158_bib75 article-title: Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model publication-title: PLoS Pathog. doi: 10.1371/journal.ppat.1009527 – volume: 25 start-page: 1969 year: 2019 ident: 10.1016/j.antiviral.2021.105158_bib85 article-title: Susceptibility of influenza A, B, C, and D viruses to baloxavir(1) publication-title: Emerg. Infect. Dis. doi: 10.3201/eid2510.190607 – volume: 222 start-page: 121 year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib105 article-title: Detection of variants with reduced baloxavir marboxil susceptibility after treatment of children with influenza A during the 2018-2019 influenza season publication-title: J. Infect. Dis. doi: 10.1093/infdis/jiaa061 – volume: 221 start-page: 1699 year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib66 article-title: Baloxavir marboxil treatment of nude mice infected with influenza A virus publication-title: J. Infect. Dis. doi: 10.1093/infdis/jiz665 – volume: 11 start-page: 2750 year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib21 article-title: Modeling mitigation of influenza epidemics by baloxavir publication-title: Nat. Commun. doi: 10.1038/s41467-020-16585-y – volume: vol. 167 start-page: 45 year: 2019 ident: 10.1016/j.antiviral.2021.105158_bib7 – year: 2021 ident: 10.1016/j.antiviral.2021.105158_bib104 article-title: Detection of variants with reduced baloxavir marboxil and oseltamivir susceptibility in children with influenza A during the 2019-2020 influenza season publication-title: J. Infect. Dis. doi: 10.1093/infdis/jiab196 – volume: 87 start-page: 369 year: 2012 ident: 10.1016/j.antiviral.2021.105158_bib138 article-title: Meetings of the WHO working group on surveillance of influenza antiviral susceptibility - Geneva, November 2011 and June 2012 publication-title: Wkly. Epidemiol. Rec. – volume: 6 year: 2011 ident: 10.1016/j.antiviral.2021.105158_bib5 article-title: Real time enzyme inhibition assays provide insights into differences in binding of neuraminidase inhibitors to wild type and mutant influenza viruses publication-title: PloS One doi: 10.1371/journal.pone.0023627 – year: 2021 ident: 10.1016/j.antiviral.2021.105158_bib140 – volume: 346 start-page: f2865 year: 2013 ident: 10.1016/j.antiviral.2021.105158_bib20 article-title: Restoring invisible and abandoned trials: a call for people to publish the findings publication-title: Bmj doi: 10.1136/bmj.f2865 – volume: 516 start-page: 361 year: 2014 ident: 10.1016/j.antiviral.2021.105158_bib101 article-title: Structural insight into cap-snatching and RNA synthesis by influenza polymerase publication-title: Nature doi: 10.1038/nature14009 – volume: 52 start-page: 1330 year: 2014 ident: 10.1016/j.antiviral.2021.105158_bib145 article-title: Universal influenza B virus genomic amplification facilitates sequencing, diagnostics, and reverse genetics publication-title: J. Clin. Microbiol. doi: 10.1128/JCM.03265-13 – volume: 76 start-page: 189 year: 2021 ident: 10.1016/j.antiviral.2021.105158_bib2 article-title: Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection publication-title: J. Antimicrob. Chemother. doi: 10.1093/jac/dkaa393 – volume: 115 start-page: 11613 year: 2018 ident: 10.1016/j.antiviral.2021.105158_bib30 article-title: The mechanism of resistance to favipiravir in influenza publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.1811345115 – volume: 363 start-page: 418 year: 1993 ident: 10.1016/j.antiviral.2021.105158_bib131 article-title: Rational design of potent sialidase-based inhibitors of influenza virus replication publication-title: Nature doi: 10.1038/363418a0 – year: 2018 ident: 10.1016/j.antiviral.2021.105158_bib39 article-title: The WHO global influenza surveillance and response system (GISRS)-A future perspective publication-title: Influenza Other Respir Viruses doi: 10.1111/irv.12565 – volume: 47 start-page: 2264 year: 2003 ident: 10.1016/j.antiviral.2021.105158_bib80 article-title: Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.47.7.2264-2272.2003 – volume: 29 start-page: 898 year: 2010 ident: 10.1016/j.antiviral.2021.105158_bib103 article-title: Reduced effectiveness of oseltamivir in children infected with oseltamivir-resistant influenza A (H1N1) viruses with His275Tyr mutation publication-title: Pediatr. Infect. Dis. J. doi: 10.1097/INF.0b013e3181de9d24 – volume: 206 start-page: 1504 year: 2012 ident: 10.1016/j.antiviral.2021.105158_bib29 article-title: Presence of oseltamivir-resistant pandemic A/H1N1 minor variants before drug therapy with subsequent selection and transmission publication-title: J. Infect. Dis. doi: 10.1093/infdis/jis571 – volume: 9 start-page: 2676 year: 2019 ident: 10.1016/j.antiviral.2021.105158_bib60 article-title: Insights into the antigenic advancement of influenza A(H3N2) viruses, 2011-2018 publication-title: Sci. Rep. doi: 10.1038/s41598-019-39276-1 – volume: 39 start-page: 706 year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib143 article-title: Baloxavir marboxil 2% Granules in Japanese children with influenza: an open-label phase 3 study publication-title: Pediatr. Infect. Dis. J. doi: 10.1097/INF.0000000000002748 – volume: 13 start-page: 522 year: 2019 ident: 10.1016/j.antiviral.2021.105158_bib47 article-title: Detection of oseltamivir-resistant zoonotic and animal influenza A viruses using the rapid influenza antiviral resistance test publication-title: Influenza Other Respir Viruses doi: 10.1111/irv.12661 – volume: 180 start-page: 104828 year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib116 article-title: Influenza A(H1N1)pdm09 virus exhibiting reduced susceptibility to baloxavir due to a PA E23K substitution detected from a child without baloxavir treatment publication-title: Antivir. Res. doi: 10.1016/j.antiviral.2020.104828 – volume: 366 start-page: 1175 year: 2005 ident: 10.1016/j.antiviral.2021.105158_bib9 article-title: Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern publication-title: Lancet doi: 10.1016/S0140-6736(05)67338-2 – volume: 14 start-page: 436 year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib88 article-title: Rapid detection of an I38T amino acid substitution in influenza polymerase acidic subunit associated with reduced susceptibility to baloxavir marboxil publication-title: Influenza Other Respir Viruses doi: 10.1111/irv.12728 – volume: 73 start-page: 383 year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib141 article-title: Polymerase acidic subunit I38T mutant influenza A(H3N2) virus isolated from a pediatric patient without prior baloxavir marboxil treatment in mie prefecture (November 2018) publication-title: Jpn. J. Infect. Dis. doi: 10.7883/yoken.JJID.2019.210 – volume: 15 start-page: 389 year: 2021 ident: 10.1016/j.antiviral.2021.105158_bib38 article-title: Comprehensive assessment of amino acid substitutions in the trimeric RNA polymerase complex of influenza A virus detected in clinical trials of baloxavir marboxil publication-title: Influenza Other Respir Viruses doi: 10.1111/irv.12821 – volume: 74 start-page: 654 year: 2019 ident: 10.1016/j.antiviral.2021.105158_bib27 article-title: Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection publication-title: J. Antimicrob. Chemother. doi: 10.1093/jac/dky462 – volume: 14 start-page: 751 year: 2009 ident: 10.1016/j.antiviral.2021.105158_bib125 article-title: Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007 publication-title: Antivir. Ther. doi: 10.3851/IMP1194 – volume: 203 start-page: 13 year: 2011 ident: 10.1016/j.antiviral.2021.105158_bib106 article-title: Dual resistance to adamantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008-2010 publication-title: J. Infect. Dis. doi: 10.1093/infdis/jiq005 – volume: vol. 196 start-page: 249 year: 2007 ident: 10.1016/j.antiviral.2021.105158_bib17 – volume: 5 year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib100 article-title: Influenza A virus field surveillance at a swine-human interface publication-title: mSphere doi: 10.1128/mSphere.00822-19 – year: 2021 ident: 10.1016/j.antiviral.2021.105158_bib110 article-title: Comprehensive profiling of mutations to influenza virus PB2 that confer resistance to the cap-binding inhibitor pimodivir publication-title: Viruses 13 doi: 10.3390/v13071196 – year: 2019 ident: 10.1016/j.antiviral.2021.105158_bib65 article-title: Treatment of highly pathogenic H7N9 virus-infected mice with baloxavir marboxil publication-title: Viruses 11 doi: 10.3390/v11111066 – volume: 24 year: 2019 ident: 10.1016/j.antiviral.2021.105158_bib121 article-title: Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019 publication-title: Euro Surveill. doi: 10.2807/1560-7917.ES.2019.24.12.1900170 – volume: 164 start-page: 91 year: 2019 ident: 10.1016/j.antiviral.2021.105158_bib69 article-title: Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012-2018 publication-title: Antivir. Res. doi: 10.1016/j.antiviral.2019.02.007 – volume: 8 start-page: 9633 year: 2018 ident: 10.1016/j.antiviral.2021.105158_bib92 article-title: Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil publication-title: Sci. Rep. doi: 10.1038/s41598-018-27890-4 – volume: 46 start-page: 977 year: 2002 ident: 10.1016/j.antiviral.2021.105158_bib28 article-title: In vitro and in vivo activities of anti-influenza virus compound T-705 publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.46.4.977-981.2002 – volume: 164 start-page: 969 year: 1991 ident: 10.1016/j.antiviral.2021.105158_bib112 article-title: Virulence of rimantadine-resistant human influenza A (H3N2) viruses in ferrets publication-title: J. Infect. Dis. doi: 10.1093/infdis/164.5.969 – volume: 175 start-page: 104718 year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib117 article-title: Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018 publication-title: Antivir. Res. doi: 10.1016/j.antiviral.2020.104718 – volume: 49 start-page: 1828 year: 2009 ident: 10.1016/j.antiviral.2021.105158_bib62 article-title: Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons publication-title: Clin. Infect. Dis. doi: 10.1086/648424 – year: 2019 ident: 10.1016/j.antiviral.2021.105158_bib90 – volume: 24 year: 2019 ident: 10.1016/j.antiviral.2021.105158_bib35 article-title: Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons publication-title: Euro Surveill. doi: 10.2807/1560-7917.ES.2019.24.3.1800666 – volume: 160 start-page: 3234 year: 2000 ident: 10.1016/j.antiviral.2021.105158_bib61 article-title: Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults publication-title: Arch. Intern. Med. doi: 10.1001/archinte.160.21.3234 – volume: 2 start-page: 395 year: 2014 ident: 10.1016/j.antiviral.2021.105158_bib87 article-title: Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(14)70041-4 – volume: 25 start-page: 2108 year: 2019 ident: 10.1016/j.antiviral.2021.105158_bib119 article-title: Human-to-Human transmission of influenza A(H3N2) virus with reduced susceptibility to baloxavir, Japan, february 2019 publication-title: Emerg. Infect. Dis. doi: 10.3201/eid2511.190757 – volume: 7 start-page: 25 issue: Suppl. 1 year: 2013 ident: 10.1016/j.antiviral.2021.105158_bib81 article-title: Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance publication-title: Influenza Other Respir Viruses doi: 10.1111/irv.12047 – volume: 57 start-page: 6668 year: 2014 ident: 10.1016/j.antiviral.2021.105158_bib15 article-title: Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2 publication-title: J. Med. Chem. doi: 10.1021/jm5007275 – volume: 385 start-page: 1729 year: 2015 ident: 10.1016/j.antiviral.2021.105158_bib19 article-title: Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials publication-title: Lancet doi: 10.1016/S0140-6736(14)62449-1 – volume: 379 start-page: 913 year: 2018 ident: 10.1016/j.antiviral.2021.105158_bib44 article-title: Baloxavir marboxil for uncomplicated influenza in adults and adolescents publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1716197 – volume: 59 start-page: 1569 year: 2015 ident: 10.1016/j.antiviral.2021.105158_bib10 article-title: Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.04623-14 – year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib67 article-title: The antiviral effects of baloxavir marboxil against influenza A virus infection in ferrets publication-title: Influenza Other Respir Viruses doi: 10.1111/irv.12760 – volume: 516 start-page: 355 year: 2014 ident: 10.1016/j.antiviral.2021.105158_bib97 article-title: Structure of influenza A polymerase bound to the viral RNA promoter publication-title: Nature doi: 10.1038/nature14008 – volume: 221 start-page: 1688 year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib132 article-title: Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection publication-title: J. Infect. Dis. doi: 10.1093/infdis/jiz656 – volume: 12 start-page: 267 year: 2018 ident: 10.1016/j.antiviral.2021.105158_bib77 article-title: Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study publication-title: Influenza Other Respir Viruses doi: 10.1111/irv.12534 – volume: 41 start-page: 742 year: 2003 ident: 10.1016/j.antiviral.2021.105158_bib135 article-title: Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network publication-title: J. Clin. Microbiol. doi: 10.1128/JCM.41.2.742-750.2003 – volume: 5 start-page: 27 year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib52 article-title: Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets publication-title: Nature microbiology doi: 10.1038/s41564-019-0609-0 – volume: 59 start-page: 2607 year: 2015 ident: 10.1016/j.antiviral.2021.105158_bib122 article-title: Characterization of a large cluster of influenza A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013-2014 influenza season in Japan publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.04836-14 – volume: 206 start-page: 1359 year: 2012 ident: 10.1016/j.antiviral.2021.105158_bib11 article-title: Determinants of antiviral effectiveness in influenza virus A subtype H5N1 publication-title: J. Infect. Dis. doi: 10.1093/infdis/jis509 – volume: 73 start-page: 3473 year: 1999 ident: 10.1016/j.antiviral.2021.105158_bib99 article-title: Direct evidence that the poly(A) tail of influenza A virus mRNA is synthesized by reiterative copying of a U track in the virion RNA template publication-title: J. Virol. doi: 10.1128/JVI.73.4.3473-3476.1999 – volume: 160 start-page: 109 year: 2018 ident: 10.1016/j.antiviral.2021.105158_bib91 article-title: In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit publication-title: Antivir. Res. doi: 10.1016/j.antiviral.2018.10.008 – year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib71 – volume: 71 start-page: 1089 year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib6 article-title: Oseltamivir resistance in severe influenza A(H1N1)pdm09 pneumonia and acute respiratory distress syndrome: a French multicenter observational cohort study publication-title: Clin. Infect. Dis. doi: 10.1093/cid/ciz904 – volume: 84 start-page: 8042 year: 2010 ident: 10.1016/j.antiviral.2021.105158_bib32 article-title: Competitive fitness of oseltamivir-sensitive and -resistant highly pathogenic H5N1 influenza viruses in a ferret model publication-title: J. Virol. doi: 10.1128/JVI.00689-10 – volume: 132 start-page: 170 year: 2016 ident: 10.1016/j.antiviral.2021.105158_bib118 article-title: Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir publication-title: Antivir. Res. doi: 10.1016/j.antiviral.2016.06.007 – volume: 188 start-page: 105036 year: 2021 ident: 10.1016/j.antiviral.2021.105158_bib93 article-title: Development of cycling probe based real-time PCR methodology for influenza A viruses possessing the PA/I38T amino acid substitution associated with reduced baloxavir susceptibility publication-title: Antivir. Res. doi: 10.1016/j.antiviral.2021.105036 – year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib84 – volume: 149 start-page: 118 year: 2018 ident: 10.1016/j.antiviral.2021.105158_bib82 article-title: Prevention and treatment of respiratory viral infections: presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference publication-title: Antivir. Res. doi: 10.1016/j.antiviral.2017.11.013 – volume: 169 start-page: 104545 year: 2019 ident: 10.1016/j.antiviral.2021.105158_bib83 article-title: Antivirals targeting the polymerase complex of influenza viruses publication-title: Antivir. Res. doi: 10.1016/j.antiviral.2019.104545 – volume: 83 start-page: 10309 year: 2009 ident: 10.1016/j.antiviral.2021.105158_bib144 article-title: Single-reaction genomic amplification accelerates sequencing and vaccine production for classical and Swine origin human influenza a viruses publication-title: J. Virol. doi: 10.1128/JVI.01109-09 – volume: 14 start-page: 460 year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib68 article-title: A rapid pyrosequencing assay for the molecular detection of influenza viruses with reduced baloxavir susceptibility due to PA/I38X amino acid substitutions publication-title: Influenza Other Respir Viruses doi: 10.1111/irv.12725 – volume: 221 start-page: 346 year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib127 article-title: Treatment-emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza publication-title: J. Infect. Dis. – volume: 328 start-page: 1272 year: 2010 ident: 10.1016/j.antiviral.2021.105158_bib8 article-title: Permissive secondary mutations enable the evolution of influenza oseltamivir resistance publication-title: Science doi: 10.1126/science.1187816 – volume: vol. 35 start-page: 1741 year: 1991 ident: 10.1016/j.antiviral.2021.105158_bib43 – volume: 182 start-page: 104906 year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib96 article-title: Detection of baloxavir resistant influenza A viruses using next generation sequencing and pyrosequencing methods publication-title: Antivir. Res. doi: 10.1016/j.antiviral.2020.104906 – volume: 342 start-page: c7258 year: 2011 ident: 10.1016/j.antiviral.2021.105158_bib56 article-title: Ensuring safe and effective drugs: who can do what it takes? publication-title: Bmj doi: 10.1136/bmj.c7258 – volume: 76 start-page: 1618 year: 1979 ident: 10.1016/j.antiviral.2021.105158_bib98 article-title: Transfer of 5'-terminal cap of globin mRNA to influenza viral complementary RNA during transcription in vitro publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.76.4.1618 – volume: 20 start-page: 478 year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib37 article-title: Successful treatment with baloxavir marboxil of a patient with peramivir-resistant influenza A/H3N2 with a dual E119D/R292K substitution after allogeneic hematopoietic cell transplantation: a case report publication-title: BMC Infect. Dis. doi: 10.1186/s12879-020-05205-1 – volume: 9 year: 2013 ident: 10.1016/j.antiviral.2021.105158_bib128 article-title: Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferrets publication-title: PLoS Pathog. doi: 10.1371/journal.ppat.1003343 – year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib115 article-title: Influenza polymerase inhibitors: mechanisms of action and resistance publication-title: Cold Spring Harbor perspectives in medicine – volume: 9 start-page: 648 year: 2012 ident: 10.1016/j.antiviral.2021.105158_bib12 article-title: The global spread of drug-resistant influenza publication-title: J. R. Soc. Interface doi: 10.1098/rsif.2011.0427 – volume: 221 start-page: 63 year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib13 article-title: Impact of the baloxavir-resistant polymerase acid I38T substitution on the fitness of contemporary influenza A(H1N1)pdm09 and A(H3N2) strains publication-title: J. Infect. Dis. doi: 10.1093/infdis/jiz418 – volume: 39 start-page: 700 year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib3 article-title: Baloxavir marboxil single-dose treatment in influenza-infected children: a randomized, double-blind, active controlled phase 3 safety and efficacy trial (miniSTONE-2) publication-title: Pediatr. Infect. Dis. J. doi: 10.1097/INF.0000000000002747 – volume: 20 start-page: 1204 year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib54 article-title: Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(20)30004-9 – volume: 54 start-page: 1102 year: 2010 ident: 10.1016/j.antiviral.2021.105158_bib16 article-title: Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.01417-09 – volume: 157 start-page: 38 year: 2018 ident: 10.1016/j.antiviral.2021.105158_bib73 article-title: Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017 publication-title: Antivir. Res. doi: 10.1016/j.antiviral.2018.07.001 – volume: 10 year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib23 article-title: Structure and function of the influenza virus transcription and replication machinery publication-title: Cold Spring Harbor perspectives in medicine doi: 10.1101/cshperspect.a038398 – volume: 56 start-page: 1197 year: 2013 ident: 10.1016/j.antiviral.2021.105158_bib137 article-title: Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the influenza resistance information study (IRIS) publication-title: Clin. Infect. Dis. doi: 10.1093/cid/cis1220 – volume: 77 start-page: 8418 year: 2003 ident: 10.1016/j.antiviral.2021.105158_bib79 article-title: Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors publication-title: J. Virol. doi: 10.1128/JVI.77.15.8418-8425.2003 – volume: 13 year: 2018 ident: 10.1016/j.antiviral.2021.105158_bib102 article-title: Influenza A/H3N2 virus infection in immunocompromised ferrets and emergence of antiviral resistance publication-title: PloS One doi: 10.1371/journal.pone.0200849 – volume: 20 start-page: 709 year: 2015 ident: 10.1016/j.antiviral.2021.105158_bib136 article-title: Single dose peramivir for the treatment of acute seasonal influenza: integrated analysis of efficacy and safety from two placebo-controlled trials publication-title: Antivir. Ther. doi: 10.3851/IMP2874 – volume: 383 start-page: 309 year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib51 article-title: Baloxavir marboxil for prophylaxis against influenza in household contacts publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1915341 – volume: 221 start-page: 337 year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib34 article-title: Baloxavir and treatment-emergent resistance: public health insights and next steps publication-title: J. Infect. Dis. – volume: 23 start-page: 157 year: 2018 ident: 10.1016/j.antiviral.2021.105158_bib45 article-title: A meta-analysis of laninamivir octanoate for treatment and prophylaxis of influenza publication-title: Antivir. Ther. doi: 10.3851/IMP3189 – volume: 50 start-page: 2395 year: 2006 ident: 10.1016/j.antiviral.2021.105158_bib86 article-title: Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.01339-05 – volume: 6 start-page: 359 year: 2005 ident: 10.1016/j.antiviral.2021.105158_bib33 article-title: Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long-term care population publication-title: J. Am. Med. Dir. Assoc. doi: 10.1016/j.jamda.2005.08.006 – volume: 32 start-page: 176 year: 2019 ident: 10.1016/j.antiviral.2021.105158_bib42 article-title: Influenza virus polymerase inhibitors in clinical development publication-title: Curr. Opin. Infect. Dis. doi: 10.1097/QCO.0000000000000532 – volume: 71 start-page: 971 year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib46 article-title: Baloxavir marboxil in Japanese pediatric patients with influenza: safety and clinical and virologic outcomes publication-title: Clin. Infect. Dis. doi: 10.1093/cid/ciz908 – year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib55 – volume: 321 start-page: 1696 year: 1989 ident: 10.1016/j.antiviral.2021.105158_bib40 article-title: Emergence and apparent transmission of rimantadine-resistant influenza publication-title: A virus in families – volume: 119 start-page: 681 year: 1997 ident: 10.1016/j.antiviral.2021.105158_bib63 article-title: Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity publication-title: J. Am. Chem. Soc. doi: 10.1021/ja963036t – volume: 458 start-page: 914 year: 2009 ident: 10.1016/j.antiviral.2021.105158_bib18 article-title: The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit publication-title: Nature doi: 10.1038/nature07745 – volume: 99 start-page: 292 year: 2018 ident: 10.1016/j.antiviral.2021.105158_bib72 article-title: An I436N substitution confers resistance of influenza A(H1N1)pdm09 viruses to multiple neuraminidase inhibitors without affecting viral fitness publication-title: J. Gen. Virol. doi: 10.1099/jgv.0.001029 – volume: 23 start-page: 335 year: 2018 ident: 10.1016/j.antiviral.2021.105158_bib126 article-title: Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study publication-title: Antivir. Ther. doi: 10.3851/IMP3212 – volume: 179 start-page: 104807 year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib1 article-title: Characterization of contemporary influenza B recombinant viruses harboring mutations of reduced susceptibility to baloxavir marboxil, in vitro and in mice publication-title: Antivir. Res. doi: 10.1016/j.antiviral.2020.104807 – volume: 83 start-page: 90 year: 2009 ident: 10.1016/j.antiviral.2021.105158_bib48 article-title: Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, south East Asia and South Africa publication-title: Antivir. Res. doi: 10.1016/j.antiviral.2009.03.003 – volume: 24 year: 2019 ident: 10.1016/j.antiviral.2021.105158_bib120 article-title: Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018 publication-title: Euro Surveill. doi: 10.2807/1560-7917.ES.2019.24.3.1800698 – volume: 83 start-page: 1121 year: 2011 ident: 10.1016/j.antiviral.2021.105158_bib89 article-title: Rapid discrimination of oseltamivir-resistant 275Y and -susceptible 275H substitutions in the neuraminidase gene of pandemic influenza A/H1N1 2009 virus by duplex one-step RT-PCR assay publication-title: J. Med. Virol. doi: 10.1002/jmv.22101 – volume: 136 start-page: 45 year: 2016 ident: 10.1016/j.antiviral.2021.105158_bib109 article-title: Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice publication-title: Antivir. Res. doi: 10.1016/j.antiviral.2016.10.009 – volume: 14 year: 2019 ident: 10.1016/j.antiviral.2021.105158_bib26 article-title: Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models publication-title: PloS One doi: 10.1371/journal.pone.0217307 – year: 2019 ident: 10.1016/j.antiviral.2021.105158_bib107 – volume: 87 start-page: 3741 year: 2013 ident: 10.1016/j.antiviral.2021.105158_bib4 article-title: T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro publication-title: J. Virol. doi: 10.1128/JVI.02346-12 – volume: 38 start-page: 360 year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib129 article-title: Next-generation sequencing: an eye-Opener for the surveillance of antiviral resistance in influenza publication-title: Trends Biotechnol. doi: 10.1016/j.tibtech.2019.09.009 – volume: 188 start-page: 105035 year: 2021 ident: 10.1016/j.antiviral.2021.105158_bib95 article-title: Susceptibility of widely diverse influenza a viruses to PB2 polymerase inhibitor pimodivir publication-title: Antivir. Res. doi: 10.1016/j.antiviral.2021.105035 – volume: 4 start-page: 1268 year: 2019 ident: 10.1016/j.antiviral.2021.105158_bib113 article-title: A humanized MDCK cell line for the efficient isolation and propagation of human influenza viruses publication-title: Nature microbiology doi: 10.1038/s41564-019-0433-6 – volume: 80 start-page: 275 year: 1987 ident: 10.1016/j.antiviral.2021.105158_bib36 article-title: Children with influenza A infection: treatment with rimantadine publication-title: Pediatrics doi: 10.1542/peds.80.2.275 – volume: 222 start-page: 957 year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib53 article-title: Treatment-emergent influenza virus polymerase acidic substitutions independent of those at I38 associated with reduced baloxavir susceptibility and virus rebound in trials of baloxavir marboxil publication-title: J. Infect. Dis. doi: 10.1093/infdis/jiaa164 – volume: 331 start-page: 10 year: 2005 ident: 10.1016/j.antiviral.2021.105158_bib94 article-title: Use of antiviral drug in poultry is blamed for drug resistant strains of avian flu publication-title: Bmj doi: 10.1136/bmj.331.7507.10 – volume: 219 start-page: 1026 year: 2019 ident: 10.1016/j.antiviral.2021.105158_bib22 article-title: Phase 2b study of pimodivir (JNJ-63623872) as monotherapy or in combination with oseltamivir for treatment of acute uncomplicated seasonal influenza A: TOPAZ trial publication-title: J. Infect. Dis. doi: 10.1093/infdis/jiy547 – volume: 16 year: 2020 ident: 10.1016/j.antiviral.2021.105158_bib76 article-title: Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission publication-title: PLoS Pathog. doi: 10.1371/journal.ppat.1008395 – volume: 217 start-page: 887 year: 2018 ident: 10.1016/j.antiviral.2021.105158_bib64 article-title: Combination therapy with neuraminidase and polymerase inhibitors in nude mice infected with influenza virus publication-title: J. Infect. Dis. doi: 10.1093/infdis/jix606 – volume: 14 start-page: 109 year: 2014 ident: 10.1016/j.antiviral.2021.105158_bib25 article-title: Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(13)70267-6 – volume: 6 start-page: 26742 year: 2016 ident: 10.1016/j.antiviral.2021.105158_bib78 article-title: Combinations of oseltamivir and T-705 Extend the treatment window for highly pathogenic influenza A(H5N1) virus infection in mice publication-title: Sci. Rep. doi: 10.1038/srep26742 – year: 2021 ident: 10.1016/j.antiviral.2021.105158_bib139 – start-page: 10857 year: 2019 ident: 10.1016/j.antiviral.2021.105158_bib24 – volume: 9 start-page: 3466 year: 2019 ident: 10.1016/j.antiviral.2021.105158_bib124 article-title: Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil publication-title: Sci. Rep. doi: 10.1038/s41598-019-39683-4 – volume: 17 year: 2021 ident: 10.1016/j.antiviral.2021.105158_bib31 article-title: Favipiravir-resistant influenza A virus shows potential for transmission publication-title: PLoS Pathog. doi: 10.1371/journal.ppat.1008937 – volume: 4 year: 2014 ident: 10.1016/j.antiviral.2021.105158_bib57 article-title: Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports publication-title: BMJ open doi: 10.1136/bmjopen-2014-005253 – volume: 206 start-page: 148 year: 2012 ident: 10.1016/j.antiviral.2021.105158_bib49 article-title: Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia publication-title: J. Infect. Dis. doi: 10.1093/infdis/jis337 – volume: 51 start-page: 1167 year: 2010 ident: 10.1016/j.antiviral.2021.105158_bib134 article-title: Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial publication-title: Clin. Infect. Dis. doi: 10.1086/656802 – volume: 76 start-page: 957 year: 2021 ident: 10.1016/j.antiviral.2021.105158_bib59 article-title: Multiple polymerase acidic (PA) I38X substitutions in influenza A(H1N1)pdm09 virus permit polymerase activity and cause reduced baloxavir inhibition publication-title: J. Antimicrob. Chemother. doi: 10.1093/jac/dkaa527 – volume: 54 start-page: 2517 year: 2010 ident: 10.1016/j.antiviral.2021.105158_bib108 article-title: In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.01739-09 – volume: 337 start-page: 874 year: 1997 ident: 10.1016/j.antiviral.2021.105158_bib41 article-title: Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group publication-title: N. Engl. J. Med. doi: 10.1056/NEJM199709253371302 – volume: 64 start-page: 1328 year: 2017 ident: 10.1016/j.antiviral.2021.105158_bib130 article-title: Impact of outpatient neuraminidase inhibitor treatment in patients infected with influenza A(H1N1)pdm09 at high risk of hospitalization: an individual participant data metaanalysis publication-title: Clin. Infect. Dis. doi: 10.1093/cid/cix127 – volume: 219 start-page: 177 year: 2019 ident: 10.1016/j.antiviral.2021.105158_bib142 article-title: Antiviral activity, safety, and pharmacokinetics of AL-794, a novel oral influenza endonuclease inhibitor: results of an influenza human challenge study publication-title: J. Infect. Dis. doi: 10.1093/infdis/jiy410 – volume: 18 start-page: 329 year: 1979 ident: 10.1016/j.antiviral.2021.105158_bib70 article-title: Are the 5' ends of influenza viral mRNAs synthesized in vivo donated by host mRNAs? publication-title: Cell doi: 10.1016/0092-8674(79)90052-7 |
| SSID | ssj0006798 |
| Score | 2.4689667 |
| SecondaryResourceType | review_article |
| Snippet | It is more than 20 years since the neuraminidase inhibitors, oseltamivir and zanamivir were approved for the treatment and prevention of influenza. Guidelines... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 105158 |
| SubjectTerms | Animals Antiviral Antiviral Agents - adverse effects Antiviral Agents - pharmacology Antiviral Agents - therapeutic use Baloxavir Dibenzothiepins - pharmacology Drug resistance Drug Resistance, Viral Enzyme Inhibitors - pharmacology Fitness Humans Influenza virus Influenza, Human - drug therapy Influenza, Human - virology Knowledge Morpholines - pharmacology Neuraminidase - therapeutic use Oseltamivir - pharmacology Polymerase inhibitor Pyridones - pharmacology SARS-CoV-2 - drug effects Triazines - pharmacology Virus Replication - drug effects Zanamivir - pharmacology |
| Title | Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group |
| URI | https://dx.doi.org/10.1016/j.antiviral.2021.105158 https://www.ncbi.nlm.nih.gov/pubmed/34363859 https://www.proquest.com/docview/2559434099 https://pubmed.ncbi.nlm.nih.gov/PMC9012257 |
| Volume | 194 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR3LahRBsAgRxYtofG3U0ILXcbenu-eR2xASNkpy0UBuTb-GjITZJdkEEojfbtX0zJhVIQeP0w-oqaquR1d1FcAnHuwsFMFSaDAk0uY-sXVNGY62MCFX0na9AY-Os_mJ_HKqTjdgb3gLQ2mVveyPMr2T1v3ItMfmdNk0029orKC2lGlKZYRkQX67lDlx-eefv9M8KMoQ63tnCa1ey_FC4BvKpaUYRMqp5y2n3u__1lB_W6B_JlLe00wHz-FZb1KyKkL9AjZCuwWPY5PJmy14ctSHz1_C3WFsSXJr2HJxfkP3UZeBNe1ZY_FgXzB0vcmcRBzssmos2ckWNUMzkblYyol1b5CGQcQVS1jFYuxhGKXLkGtWDf_Nurcjr-DkYP_73jzp-y8kTkm-SrgRKZpnquCZ48orn4vCCStK40ulUu-c9zYzvHTGZkoFRF9ao1dqheHcFzPxGjbbRRveAnMldyZXXgTpUG2mVlDIh9ehcCEzpZ9ANuBcu744OfXIONdDFtoPPRJLE7F0JNYEZuPGZazP8fCW3YGoeo3VNGqRhzd_HNhA40Gk6Ippw-LqUpNvJgW6y-UE3kS2GCESUqCcUziTrzHMuICKfK_PtM1ZV-y7pNinyrf_B-h38JS-Yg7ie9hcXVyFD2hLrexOd1h24FF1-HV-_AtyuyJL |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR3LahRBsAgJPi6i8bUmagtex92e7p5HbkswbDSbiwnk1vRryEiYXZKNEEG_PVXTM6OrQg5e-wE19a6p6iqA9zzYSSiCpdRgSKTNfWKriiocbWFCrqRtZwPOj7PZqfx0ps42YL9_C0NllZ3ujzq91dbdyrjD5nhZ1-Mv6KygtZRpSm2EZIFx-5ZE8aUxBh9-_qrzoDRDbPCdJXR8rcgLoa-pmJaSECmnobechr__20T97YL-WUn5m2k6eAyPOp-STSPYT2AjNNtwL06ZvNmG-_Muf_4UfhzGmSTfDVsuLm7oh9RVYHVzXluU7EuGsTf5k4iEPTYdenayRcXQT2Qu9nJi7SOkfhGRxRI2ZTH50K_S35BvbNp_N2sfjzyD04OPJ_uzpBvAkDgl-SrhRqTon6mCZ44rr3wuCiesKI0vlUq9c97bzPDSGZspFRB9aYVhqRWGc19MxHPYbBZNeAnMldyZXHkRpEO7mVpBOR9ehcKFzJR-BFmPc-267uQ0JONC92VoX_VALE3E0pFYI5gMF5exQcfdV_Z6ouo1XtNoRu6-_K5nA42SSOkV04TF9ZWm4EwKjJfLEbyIbDFAJKRARadwJ19jmOEAdfle32nq87bbd0nJT5W_-h-g38KD2cn8SB8dHn_egYe0EwsSd2FzdXkdXqNjtbJvWsG5Bdi7I9k |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Influenza+polymerase+inhibitor+resistance%3A+Assessment+of+the+current+state+of+the+art+-+A+report+of+the+isirv+Antiviral+group&rft.jtitle=Antiviral+research&rft.au=Ison%2C+Michael+G&rft.au=Hayden%2C+Frederick+G&rft.au=Hay%2C+Alan+J&rft.au=Gubareva%2C+Larisa+V&rft.date=2021-10-01&rft.issn=1872-9096&rft.eissn=1872-9096&rft.volume=194&rft.spage=105158&rft_id=info:doi/10.1016%2Fj.antiviral.2021.105158&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0166-3542&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0166-3542&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0166-3542&client=summon |